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ABSTRACT

The past few years have witnessed considerable growth in synthetic polymer
chemistry and physics, biomaterials science, and nano-scale engineering. Research on
polypeptide multilayer films, coatings, and microcapsules is located at the intersection of
these areas and are promising materials for applications in medicine, biotechnology,
environmental science. Most envisioned applications of polypeptide multilayers have a
biomedical bent. This dissertation on polypeptide multilayer film applications covers key
points of polypeptides as materials, means of polymer production, film preparation, film
characterization methods, and key points of current research in basic science. Both
commercial and designed peptides have been used to fabricate films for in-vitro
applications such as antimicrobial coatings and cell culture coatings and also
microcapsules for drug delivery applications. Other areas of product development include
artificial red blood cells, anisotropic coatings, enantioselective membranes, and artificial
viruses.
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CHAPTER 1

INTRODUCTION

1.1

There’s Plenty of Room at the Bottom

On December 29, 1959, at the California Institute of Technology, physicist
Richard Feynman gave a talk titled “There's Plenty of Room at the Bottom” [1], The
lecture’s title would seem to be a pun on the title of a 1959 British film, Room at the
Top [2]. The story is about a money- and status-seeking blue-collar worker (a lowly
atom) willing to do whatever it might take to climb the ladder to success (become an
essential component of the complex network of interactions that characterize a living
organism). Simone Signoret won the Oscar for best actress for her role in the film [2] as
the epitome of sexy, womanly vulnerability—an element of the seductive vision that
motivates the sojourn of the atom from obscurity to stardom. At the time the film was
current, celebrities bound for Hollywood arrived more often than not by train and
disembarked not in working-class Los Angeles but in pleasant Pasadena [3]. Little
imagination is needed to guess that an evening with Simone was the dream of many a
science or engineering student at the then virtually all-male California Institute of
Technology, and that she was the subject of a good deal of off-topic chat. Feynman’s
lecture is now generally taken as the genesis of nanotechnology. His thinking on the
matter may have been stimulated by knowledge of or interaction with other notables at

1

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

Caltech, for instance, T. Morgan (chromosome theory of heredity), L. Pauling (genetic
basis of sickle-cell anemia), and M. Delbriick (bacterial virus structure and function)
(Nobel laureate, Medicine or Physiology, 1969). In his talk Feynman unveiled the
possibilities available in the molecular world and his vision spawned the discipline of
nanotechnology. Because ordinary matter has so many atoms, he showed that there is a
remarkable amount of space in which to build.
Atoms are unbelievably small and their properties utterly foreign, which makes
our intuition and knowledge of the meter-scale world useless at best and misleading at
worst. When men and women first restructured matter to fit their needs, they invented a
top-down approach and used tools to shape and transform existing matter.
Nanotechnology takes an opposite approach in which nano-scale devices are built using
a bottom-up approach atom by atom [4]. It is important to understand that atoms are not
just small; they are ‘a special kind’ of small. The positioning of individual xenon atoms
on nickel (110) surface at IBM is a successful example of nanotechnology [5].
1.1.1 Biotechnology to Bionanotechnology
Biotechnology grew from the use of natural enzymes to modify genetic code,
which was then used to modify entire organisms. This revolution has led to myriad
applications, including commercial production of hormones and drugs, elegant methods
for diagnosing and curing infections and genetic diseases, and engineering of organisms
for specialized tasks such as bioremediation and disease resistance. Biotechnology took
several decades to gather momentum but nanoscale understanding and atomic details
were not really important. Existing functionalities were combined to achieve the end
goal. Bionanotechnology is a subset of nanotechnology, nanotechnology that looks to
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nature for its start and requires human design and construction at the nanoscale level.
Bionanotechnology has many faces, but all share a central feature: the ability to design
molecular machinery to atomic specifications. It is closely married to biotechnology but
adds the ability to design and modify the atomic level details of the objects created.
1.1.2 Proteins and Polypeptides
Polypeptides form one of four classes of biological macromolecules—the others
being nucleic acids, polysaccharides, and phospholipids [6], The first determination of
the chemical structure of a bioactive peptide, cow insulin, was achieved by F. Sanger
(Nobel laureate, Chemistry, 1958) in the early 1950s. A key feature of amino acid
subunits of a polypeptide is their structure. An amino group, a carboxyl group, a
hydrogen atom, and a variable side chain, R, constitute the substituents of the central
carbon. There are 20 usual side chains in nature. The number of possible non-natural
side chains is practically unlimited, and scores of novel ones are available from
commercial sources for abiotic peptide synthesis. Amino acids are chiral: each of the
natural ones has a right-handed form (d isomer) and a left-handed form (1 isomer) with
the exception glycine, which has just a hydrogen atom for its R side chain. All amino
acids in all proteins in all known organisms are 1isomers.
There are four hierarchical levels of peptide-based structures, and they were first
defined by K. Linderstrom-Lang in the 1950s [7]. Primary structure denotes the sequence
of amino acid residues in a polypeptide chain. The most common types of secondary
structure, a-helices and /3-sheets, were predicted by L. Pauling (Nobel laureate,
Chemistry, 1954) and R. Corey in the early 1950s and visualized in atomic-resolution
protein structures shortly thereafter. Helices and sheets are characterized in part by
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having distinctive patterns of hydrogen bonds (relatively weak electrostatic interactions)
formed between chemical groups in the polypeptide backbone. Nearly all known protein
structures comprise at least one obelix or /3-sheet [8]; secondary structures can also form
in peptides that do not fold into proteins [9]. Tertiary structure refers to the relative
spatial orientation of secondary structure elements and the noncovalent contacts between
amino acids, as in the small muscle protein myoglobin. Quaternary structure is the
relationship between polypeptide chains when more than one is involved in forming the
overall protein structure, as in the blood protein hemoglobin, a structural relative of
myoglobin.
When properly folded and biologically functional, a protein is said to be in it’s
native state. Folded protein structure was first visualized at atomic resolution in the late
1950s and early 1960s: sperm whale myoglobin and horse heart hemoglobin by J.
Kendrew and M. Perutz (Nobel laureates, Chemistry, 1962), respectively, at Cambridge
University, and hen egg white lysozyme by D.C. Phillips at Oxford University. Since
then, the number of protein structures determined at or near atomic resolution has risen
exponentially with each passing year. A disulfide bond is a natural type of covalent cross
link that can form between cysteine side chains. Disulfide bonds stabilize protein
structure by reducing the entropy of the polymer chain, particularly in a denatured state
(for example, [10]). Ribonuclease A is a small protein with four native disulfide bonds. In
the early 1960s C. Anfmsen (Nobel laureate, Chemistry, 1972) showed that all the
instructions required for the ribonuclease polypeptide to go from a denatured state in
which no disulfide bonds were intact to native protein structure in water were encoded in
the amino acid sequence. In some cases, at least, acquisition of biologically functional
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protein structure from a disordered conformation is driven by a minimizing the Gibbs
free energy of the protein-solvent system. Genome-sequencing efforts have revealed that
the myriad of DNA-encoded polypeptide chains in the different living organisms on
Earth fold into a comparatively tiny number of qualitatively different structures [8],
Several broad structural classes of proteins have been identified. In globular
proteins (for example, myoglobin), the polypeptide folds into a highly compact, ball-like
shape. Fibrous proteins found in hair, tendons, and spider silk tend to be elongated.
Elastin, for example, found in skin and lung, can be stretched without tearing. Formed of
loose and unstructured polypeptide chains, this protein provides the elasticity needed to
fulfill its biological role. Membrane proteins (such as the insulin receptor) are embedded
in the plasma membrane of a cell. Proteins can also be classified according to function
[8]. Enzymes, such as lysozyme, catalyze covalent bond formation or rupture in specific
chemical reactions. Structural proteins provide mechanical support for cells and tissues.
Transport proteins, such as hemoglobin, carry small molecules and ions. Motor proteins
generate force, causing muscle contraction and allowing movement in the case of skeletal
muscle myosin. Signaling proteins and peptides, such as insulin, are chemical signals that
control physiological function, often by binding non-covalently to receptor proteins
embedded in the plasma membrane which transmit the signal inside or outside the cell.
Storage proteins bind ions or metabolites and store them. Gene-regulatory proteins switch
gene expression on and off in response to environmental cues. Antibodies bind specific
antigens and stimulate the immune system to protect the body from an invading
pathogen. Proteins are nanometer-scale machines of remarkable functional variety.
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Details of protein structure and function, revealed by decades of study, form a library of
motifs for the design of polypeptides for multilayer film assembly.

1.2 Designed Polypeptides
Amino acids can be joined together to form a peptide or polypeptide. They are
called peptides because following a condensation reaction, the carboxyl group of one
amino acid joins to the amino group of another, and a covalent bond is formed.
Chemically this is an amide bond but when it occurs in proteins it is given the name
peptide bond. The peptide bond has an unusual property that has a marked effect on the
rigidity and structure of a polypeptide chain. It has a partial double-bond character,
caused by the resonance of electrons rapidly moving between the oxygen and nitrogen to
make the C-N bond a partial double bond. The consequence of this arrangement is that
the peptide bond is very rigid because C=N is much less flexible than a C-N bond [11].
The 19 a-amino acids in peptides and proteins (proline is an imino acid) consist of a
carboxylic acid (-COOH) and an amino (-NH2 ) functional group attached to the same
tetrahedral carbon atom, the a-carbon. The R-groups, which distinguish one amino acid
from another, are attached to the alpha-carbon (except for glycine, for which the R-group
is hydrogen). The fourth substituent of the tetrahedral a-carbon of amino acids is
hydrogen. The two broad classes of amino acids are based upon whether the R-group is
hydrophobic or hydrophilic. Figure 1.1 shows peptide bond formation.

0

+
OH

0

H

\
/
H

N — R'
H

Figure 1.1. Peptide bond formation [11].
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Hydrophobic amino acids tend to repel the aqueous environment and, therefore,
reside predominantly in the interior of proteins. This class of amino acids does not ionize
nor participate in the formation of H-bonds. Non-polar side chains consist mainly of
hydrocarbon. Any functional groups they contain are uncharged at physiological pH and
are incapable of participating in hydrogen bonding. The non-polar amino acids include
alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline,
tryptophan, tyrosine and valine. The hydrophilic amino acids tend to interact with the
aqueous environment, are often involved in the formation of H-bonds and are found
predominantly on the exterior surfaces proteins or in the reactive centers of enzymes. The
polar amino acids include arginine, asparagine, aspartic acid (or aspartate), glutamine,
glutamic acid (or glutamate), histidine, lysine, serine, and threonine. Polar side chains
contain groups that are either charged at physiological pH or groups that can participate
in hydrogen bonding [6],
Polymers

of amino

acids

form

one

of the

four major

classes

of

biomacromolecules and constitute about half of the dry mass of a living organism [12].
Polypeptides are the structural building blocks of materials ranging from hair and tendons
in mammals to the silk produced by insects and spiders. The enormous range of possible
amino acid side chains, of which the 20 usual ones are but a small subset, makes
polypeptides particularly promising molecules for controlled design features. Degree of
polymerization, degree of dispersity, and chemical modification of chain termini or side
chains can be controlled, depending on the method of synthesis or purification protocol.
Considering the 20 usual amino acids alone, ~1041 distinct chemical structures of
unmodified 32-mer polypeptides can be synthesized. Modem methods of synthesis
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enable realization in the laboratory of a large proportion of this vast range of possibilities.
Important design elements are amino acid side chains that are charged at neutral pH,
hydrophilic side chains that are polar but uncharged at neutral pH, hydrophobic side
chains, side chains capable of hydrogen bonding, and side chains that are uncharged.
A unique feature of polypeptides is their ability to form secondary structure. It is
known from protein research that various sequences of amino acid show a preference to
adopt a type of secondary structure, a-helix or /3-sheet [13]. Both types are stabilized by
hydrogen bonds which form between chemical groups in the polymer backbone. The
ability of a peptide to fold into a specific structure, the control one can have over peptide
sequence, and the range of possible ways of integrating polyelectrolytes with other
materials, for example colloidal particles, together provide a remarkable range of
opportunities for the design of nanoscale materials. To summarize, hydrophobicity, linear
charge density, propensity to form secondary structure at neutral pH, and ability to form
chemical crosslinks can be varied according to purpose by design of sequence. Shown in
Figure 1.2, are molecular models of two designed polypeptides.

9.4 nm
Figure 1.2. Molecular models of designed peptides.
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1.3 Electrostatic Layer-by-Laver Assembly (LBL)
Layer-by-layer assembly (LBL) is a method of making a multilayer thin film from
oppositely charged species [14-18] deposited in succession on a solid support. The
method has attracted interest because it is simple and considerably more versatile than
other techniques of thin film preparation, for example Langmuir-Blodgett deposition. The
basic principle of assembly, coulombic attraction and repulsion, is far more general than
the type of adsorbing species or surface area or shape of support [17]. Film assembly can
be described as the kinetic trapping of charged polymers from solution on a surface.
Multilayer film formation is possible because of charge reversal on the film surface after
each polyion adsorption step [19-34]. Surface charge thus depends on the last adsorbed
layer, permitting a degree of control over surface and interface properties. A high density
of charge in the adsorbing species will result not only in strong attraction between
particles in neighboring layers, but also in strong repulsion between like-charged particles
in the same layer. That is, electrostatics both drives film assembly and limits it. Several
layers o f material applied in succession create a solid, multilayer coating. Each layer of
can have a thickness on the order of nanometers, enabling the design and engineering of
surfaces and interfaces at the molecular level. Subtle changes in organization and
composition can influence film structure and functionality. The layering process is
repetitive and can be automated, important for control over the process and
commercialization prospects. Constituents of a film could be bioactive or bioresponsive
materials. Since the early 1990s there has been considerable interest in making multilayer
films from linear ionic polymers [14, 35]. Such films are being developed for of a variety
o f applications: for example, contact lens coatings, sustained-release drug delivery
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systems, biosensors, and functionally advanced materials with various electrical,
magnetic, optical, and antimicrobial properties [14-18, 36-42, 43]. Figure 1.3 shows a
schematic of the LBL process

m
P olyanlons

Figure 1.3. Schematic of Layer-by-Layer (LBL) technique.

Many different polyelectrolytes have been studied in this context. Examples are
poly(styrene sulfonate) (PSS), poly(allylamine hydrochloride) (PAH), poly(acrylic acid)
(PAA), and poly (diallyldimethylammonium chloride) (PDADMAC). These polymers are
called “common” or “conventional” in view of their ready availability from commercial
sources and their having been studied extensively. Polyelectrolyte structure, however,
would appear to have little effect on whether LBL is possible if the ionic groups are
accessible. The polymer chains, once assembled into a multilayer film, tend to become
highly interpenetrated whether strong polyelectrolytes or weak ones [44, 45]. Besides
synthetic polymers, “natural” polyelectrolytes such as nucleic acids, proteins,
polysaccharides, and charged nano-objects such as virus particles and membrane
fragments have been assembled into multilayer films [46, 47].
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1.4

Advantages of LBL

A multilayer film or coating of nanometer-thick layers can be fabricated by
sequential adsorption of oppositely-charged polyelectrolytes on a solid support by a
method known as layer-by-layer assembly (LBL). No special apparatus is required for
LBL, and the film can be made under mild, physiological conditions. LBL is a simple
and benign fabrication process. The material production is relatively straightforward,
and the process is amenable to automation, and scalable, and it enables exquisite
control over structure and function at the nanometer scale. A diverse range of materials
and surfaces are suitable for deposition as the only criteria is the net charge on the
adsorbing species at the assembly pH and the process is independent of the size, shape,
and composition of the surface. The process also allows for numerous control variables
during the deposition process, for example concentration, ionic strength, adsorption
time, pH, and temperature. Furthermore, post-fabrication processing potential is also
broad. An astronomical number of possible layer architectures can be incorporated into
the final film, and the process is environmentally friendly and involves no hazardous
chemicals. The only cost incurred in this process would be the cost of the materials
involved. Recently, alternatives to the repetitive assembly of layers by dipping [14]
have been developed for the fabrication of ionic polymer films. An iterative spraying
method of film assembly has been introduced by Schlenoff et al [48]. The use of spincoaters has been demonstrated by Hong et al. [49, 50] and Wang et al. [51]. More
recently, the Strasbourg polyelectrolyte film group [52, 53] has shown that continuous
and simultaneous spraying of polyanion and polycation solutions [54, 55] onto a
vertically-oriented charged surface can create a uniform film that grows continuously
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with spraying time. The advantages of LBL fabrication process for multilayer film
production are summarized in Table 1.1.

Table 1.1. Advantages of LBL.
Further applications
Non-polyelectrolytes, Polyelectrolytes
Non-biological surfaces (e.g. plates, stents,
contact lenses), Colliods (e.g. latex or
calcium
carbonate micro particles),
Biological ‘cells’ (e.g. viruses or red blood
cells)
Concentration Adsorption time Ionic
strength,
Temperature,
Solvent
Numerous control variables for deposition
composition
Broad pre- and post-fabrication processing pH, Ionic strength, Temperature
potential

General advantage
Diverse materials available
Independent of surface shape and size,
Astronomical number of possible layer
architectures,
Environmentally-friendly
process, Low-cost production process

1.5

Weak Polvelectrolytes

In a water-soluble polyelectrolyte with a fixed fraction of equally charged
monomers, if the net charge arises from strong dissociating groups, they will remain
charged throughout a pH range. This is the case of a quenched or strong polyelectrolyte.
If the net charge arises from reversible proton transfer with the solvent and is therefore
pH dependent, it is called an annealed or weak polyelectrolyte. If the net charge consists
of both positive and negative contributions, the polymer is a polyampholyte. A
polypeptide is a weak polyelectrolyte. Depending on sequence and pH, a polypeptide
might be a polyampholyte.
The linear charge density of a weak polyelectrolyte is “tunable” by simple
adjustment of pH. Many such polymers are essentially fully charged at neutral pH. The
pKa of ionizable groups in a weak polyelectrolyte, however, will be sensitive to the local
electronic environment, and the net charge can shift significantly from the solution value
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on formation of a polyelectrolyte complex or film [56-63]. Extensive study by Rubner
and colleagues has revealed key aspects of the LBL assembly behavior of “conventional”
weak polyelectrolytes [44], e.g., PAA and PAH. Fabrication of films from these polymers
represents a type of molecular-level blending process. Control of the type and extent of
blending enables manipulation of the bulk and surface properties of the resulting film.
Weak polyelectrolytes thus afford great latitude for controlling internal and surface
material composition, thickness, molecular organization, ionic “crosslink” density,
molecular conformation, wettability, swelling behavior, surface properties, and reactive
functional groups. Possible molecular conformations in polypeptide films will include not
only the “flat” and “loopy” structures of conventional polyelectrolyte adsorption [64] but
also a-helices and /3-sheets. The pH sensitivity of weak polyelectrolytes enables changes
in film morphology after film preparation. Such changes can be reversible or irreversible.
Control of internal and surface composition of weak polyelectrolyte films is
achieved by control o f amount of polyelectrolyte adsorbed [65], Another approach is to
alter the charge density of the adsorbed polyelectrolyte by changing the pH of solution of
the other polyion. This alters the surface charge while keeping the internal structure
similar, enabling creation o f designer films using the same polyions. Assembly of
polyelectrolytes of different charge density allows non-stoichiometric pairing of polyions.
The result in the case of PAA and PAH is a swellable film. Such films can bind metal
cations from aqueous solution by ion exchange with the protons of the PAA carboxylic
acid groups [66].
A final point about weak polyelectrolyte films is pH-driven reorganization of
morphology. Under certain circumstances, notably when the internal film structure is
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characterized by fully charged, “loopy,” randomly-arranged chains, reorganization can
result in the formation of micropores. For example, exposing a pFI 3.5 PAA/pH 7.5 PAH
film to pH 2.4 for 15 s and then rinsing with water leads to phase separation and
micropore formation [58], The phenomenon has been exploited to “load” polyelectrolyte
microcapsules with various soluble molecules, including enzymes. Membrane fragments
have been assembled into multilayer films [47],

1.6

Polypeptide Multilayer Film Fabrication by LBL

A polypeptide multilayer film is defined as a multilayer film made of
polypeptides. In some instances another type of polymer is involved in the fabrication
process, for instance a chemically-modified polypeptide, [67] a non-biological organic
polyelectrolyte, [68] or a polysaccharide, [69]. A polypeptide film might be deposited to
confer specific biofunctionality on a surface that was otherwise bioinert, or to convert a
bioactive surface into one not adhesive to cells [70-74], Study of polypeptide multilayer
films constitutes a confluence of two more mature streams of inquiry: peptide structure
and function, a significant area of basic research since about 1905, and polyelectrolyte
multilayer films, developed since the early 1990s. Multilayer films are promising for the
development of applications which encompass some of the following desirable features:
anti-fouling, biocompatibility, biodegradability,

specific biomolecular

sensitivity,

edibility, environmental benignity, thermal responsiveness, stickiness or non-stickiness.
Polypeptides are ideally suited for such applications by virtue of their biochemical
nature- the control one can have over chemical structure in various approaches to
polymer synthesis, the ability to control formation of secondary structure, or the
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availability of genomic data. The properties of polypeptides and multilayer films are
summarized in Table 1.2.

Table 1.2. Properties of polypeptides and multilayer films.
Polypeptides
“Designable”

LbL multilayer films
Nano-meter scale control over thickness

Can be produced en masse in bacteria

Engineered architecture

Susceptible to proteolysis

Arbitrary surface area

Biodegradable

Arbitrary surface shape

Edible

Simple methodology

Environmentally benign

Environmentally-ffiendly methodology

Sequence-specific immunogenecity

Low-cost methodology

Predictable a-helix//3-sheet propensity

Can be used to make capsules

Fold into proteins in some cases

Suitable for a broad range of particles

Specific bioactivity in some cases

Interesting material properties

Control over structure and synthesis could also be important for using designed
polypeptides to gain insight on the nature of polyelectrolyte multilayer film assembly
and stability. The important point here is that one can have control over this range of
variables even when polypeptides are selected for more specific reasons, for example
the extent of control over polymer synthesis, biocompatibility, or environmental
benignity. Given a peptide design, synthesis is accomplished by a chemical method or a
biological method. The approach to synthesis will depend on sequence, degree of
polymerization, required fidelity with respect to sequence or length, cost, and
production time.Common fabrication concerns in preparing polypeptide multilayer
films, coatings, or capsules are summarized in Table 1.3.
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Table 1.3. Variables in polypeptide multilayer film/coating/capsule fabrication.
General area

More specific considerations
Sequence

Peptide synthesis

Crosslinking
Internal properties
External properties
Transport
Half-life

Length
Fidelity
Yes
No
Active
Inactive
Bioactive
Non-bioactive
Small molecules
Macromolecules
Ex-vitro
In-vivo

If “natural” crosslinking of the film is required, for example to stabilize film
structure, at least one of the peptides must feature the amino acid cysteine. The thiol
group of cysteine provides an “inherent” means of crosslinking polypeptides under
mild reaction conditions. A polypeptide multilayer film or capsule will have surface
(“external”) properties which make it bioactive or non-bioactive. Examples of bioactive
properties are anti-microbial activity, immunogenicity, and cytophilicity. Although
some antibiotics are small molecules, and some non-protein polyelectrolytes are nonimmunogenic or cytophilic, use of polyeptides enables a great degree of control over
bioactive properties in defined and “natural” ways. Non-bioactive properties include
hydrophobicity, hydrophilicity, and physical protein adsorption. Quite apart from any
biofunctionality a polypeptide might exhibit, the polymer is a mere chemical on some
level. In general, then, bioactive materials will encompass features of non-bioactive
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materials. The film or capsule will be “inactive” or “active” with regard to “internal”
properties. For example, an active film might feature an entrapped functional enzyme
or some other type of chemically reactive agent. Transport and release properties of the
film or capsule will depend on the choice of peptides and method of fabrication. The
film preparation process could be optimized for the transport of small molecules which
may or may not be soluble in water or some other solvent, or release of
macromolecules, for example nucleic acids and peptides. Other recent advances in
polypeptide science outside the area of multilayer films are peptides that self-assemble
into various types of nanostructure, [75-78] diblock copolypeptides that self-assemble
into spherical vesicular assemblies, [79] or peptide block copolymers that self-assemble
into fibrils [80]. The application areas of polypeptide multilayer films are shown in
Table 1.4.

Table 1.4. Why study polypeptide multilayer films?
Science

Technology

Physics

Engineering

“Unusual” backbone role of entropy in adsorption

Coatings

Primary structure, role o f interactions

Capsules

Secondary structure and nano-scale organization

Self assembly

Chemistry

Bio-based materials production

“Inherent” covalent crosslinking

Medicine

Similarity to protein folding and stability

Tissue engineering

Biochemical properties

Artificial cells

Biology

Immunogenecity

“Inherent” bioactivity

Edibility

Environmental benignity

Implant Coatings

Biodegradation

Drug delivery vehicles
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1.7 Conclusions
Polypeptides are weak polyelectrolytes these biomacromolecules are of
fundamental importance to life as we know it. One cannot assume that what has been
learned about multilayer film fabrication from extensive study of non-polypeptide
polyelectrolytes, including weak polyelectrolytes, will form a sufficient basis for
predicting the physical, chemical and, most important, biological properties of
polypeptide multilayer films. One gathers from what has been said thus far that
polypeptide multilayer film development combines knowledge of physics, chemistry,
biology, medicine, biotechnology, and engineering. There is great promise for the
development of useful films and multifunctional coatings. Developments in synthetic
chemistry and biotechnology are likely to prove crucial to commercialization efforts,
many of them likely to be aimed toward applications in medicine and biotechnology.
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CHAPTER 2

POLYPEPTIDE MULTILAYER FILMS

2.1 Introduction
Polypeptides are weak polyelectrolytes. Much is known about peptide structure
and function, and about conventional weak polyelectrolytes in LBL. It does not follow,
however, that physical properties of polypeptide films can easily be predicted from
knowledge o f amino acid sequence and weak polyelectrolyte LBL alone. Polyelectrolyte
self assembly is very complex. Bulk film properties will arise from details of interactions
between constituent molecules, and predictions of chemical and biological properties of a
polypeptide film will be all the more speculative, at least in general terms, even if
environmental benignity can generally be assumed. Considering the 20 usual amino acids
alone, simple combinatorics says there are 3220 (~1041) chemically distinct polypeptides
32 residues long. Important for commercial prospects of polypeptide multilayer films, a
large proportion of the possible peptide structures can be realized; moreover, large
quantities of material can be prepared by solid-phase synthesis or genetic engineering of
bacteria. The physical, chemical and biological properties of polypeptide multilayer films
can be studied using various techniques that have been applied to other polyelectrolyte
multilayer films.

The choice of technique, however, will depend on the intended

application of the multilayer film.

19
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2.2

Polypeptide Synthesis Purification and Characterization

There are two basic approaches to designed polypeptide production: abiotic
synthesis and biotic synthesis. Abiotic synthesis, whether solution phase or solid phase,
the preferred approach for most laboratory studies of

film assembly, stability, and

functionality, and biotic synthesis the logical option for large-scale preparation of short
peptides or production of long ones. The abiotic approach also permits the study of
polypeptides containing non-natural amino acids. Nowadays it is possible to prepare kg
quantities of short peptides by chemical synthesis. Solution-phase synthesis is practically
useful for preparation of homopolypeptides or peptides of defined composition but
indefinite sequence only [81, 82]. Degree of polymerization in the solution-phase
approach will be determined by the synthesis conditions, for example duration of reaction
and temperature, and they must be worked out by empirical study. Solid-phase synthesis,
by contrast, starts with an Na-derivatized amino acid attached to an insoluble resin via a
suitable linker molecule [83]. The No: protecting group is removed in a deprotection step,
and the next amino acid in the chain (also Na-protected) becomes coupled. This process
is imperfect, but certain methods, for instance double coupling, give good overall
efficiency. The deprotection/coupling cycle is repeated until the desired sequence of
amino acids is generated. The peptide-linker support is cleaved, yielding the peptide and
side chain protecting groups. And finally the protecting groups are removed. Solid-phase
synthesis has made it possible to obtain useful amounts of a specific peptide on a routine
basis.
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2.2.1 Solid Phase Peptide Synthesis (SPPS)
Solid-phase peptide synthesis was pioneered by Merrifield [84], resulting in a
paradigm shift within the peptide synthesis community. The concept of SPPS is to retain
chemistry proven in solution, but to add a covalent attachment step (anchoring) that links
the nascent peptide chain to an insoluble polymeric support. An appropriate polymeric
support (resin) must be chosen that has adequate mechanical stability, as well as the
desired physiochemical properties that facilitate solid phase synthesis. The synthesis
beads will retain strong bondage to the peptides until cleaved by a reagent such as
trifluoroacetic

acid.

The

anchored

peptide

is

extended

by

a

series

of

deprotection/coupling cycles, which are required to proceed with exquisitely high yields
and fidelities. It is the essence of solid-phase approach that reactions are driven to
completion by the use of excess soluble reagents, which can be removed by simple
filtration and washing without manipulative losses. Because of the speed and simplicity
of the repetitive steps, carried out in a single reaction vessel at ambient temperature, the
major portion of the solid-phase approach is readily amenable to automation. Due to
amino acid excesses used to ensure complete coupling during each synthesis step,
polymerization o f amino acids is common in reactions where each amino acid is not
protected. To prevent this polymerization, protective groups are used. The Fmoc (9fluorenylmethyl carbamate) is currently a widely used protective group that is generally
removed from the N terminus of a peptide in the iterative synthesis of a peptide from
amino acid units. Once the desired linear sequence has been assembled satisfactorily on
the polymeric support, the anchoring linkage must be cleaved. Depending on the
chemistry o f the original handle and on cleavage reagent selected, the product from this
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step can be a C-terminal peptide acid, amide, or other functionality. The advantage of
Fmoc is that the peptide is cleaved under very mild basic conditions. This adds additional
deprotection phases to the synthesis reaction, creating a repeating design as shown in
Figure 2.1.
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Figure 2.1. Schematic diagram of solid phase peptide synthesis [85].
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The peptide synthesis in our laboratory was conducted on a Protein Technologies
Inc. SYMPHONY which uses Fmoc chemistry to synthesize up to 12 peptides
simultaneously. The synthesis scale is 5-100 pmol, and peptide-resin cleavage is
performed on the instrument. The software allows us to enter the desired sequences and
scale of synthesis and the amounts of reagents required are calculated. The instrument is
programmed according to the desired sequences and the amounts of reagents required are
calculated. Clean reaction vessels are used and resin is added in the required amount
depending on the scale of synthesis. The resin is first swelled for a few minutes in DMF
and drained the resin is also washed with DMF after each amino acid coupling. Fmoc
deprotection after each amino acid coupling is accomplished using 20% piperidine in
DMF, with mixing using mitrogen gas for a given time after each step. The resin is then
washed with DMF. The first amino acid is coupled to the Fmoc-deprotected N-terminal
amine of the resin, or a previously coupled amino acid, using a solution of amino acid
dissolved in HBTU and 0.4 M N-methylmorpholine in DMF while mixing using nitrogen
gas. Once the coupling of an amino acid is complete, the resin is washed, the Fmoc group
deprotected with piperidine, and the resin is washed again to prepare it for the next
coupling. This process is repeated until all the amino acids are coupled. The resin is
allowed to dry and treated with an appropriate cocktail solution to cleave the peptide
from the resin. The resin is then filtered away and the cocktail solution is added to cold
ether to precipitate the dissolved peptides. The peptide suspension is then centrifuged and
the ether decanted. This process is repeated a number of times to remove the scavengers
and traces of trifluoroacetic acid followed by evaporation and lyophilization of the
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peptide. The choice of the cocktail solution depends on the peptide sequence as shown in
Figure 2.2.
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Figure 2.2. Flowchart for selecting cocktail solution.
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2.2.2 High Performance Liquid Chromatography (HPLC)
High-performance liquid chromatography (HPLC) is an essential tool for the
identification, purification and characterization of biomacromolecules. It is used mostly
in biotechnology and pharmaceutical industries in all stages of a process from research
and development to quality assurance and validation. The aim of the research and the
molecular nature of the investigated molecules determine the choice of the
chromatographic method and the type of high-performance equipment. Currently, most
classes of biomacromolecules, including amino acids, peptides, proteins, carbohydrates,
nucleic acids and lipids are analyzed primarily by HPLC. Several basic modes of HPLC
are currently in use for peptide and protein analysis and purification, which include sizeexclusion, ion-exchange, normal-phase, hydrophobic interaction, reversed-phase and
hydrophilic interaction chromatography.
Reversed-phase High-performance liquid chromatography (RP-HPLC) techniques
are very versatile and flexible, and they dominate the application world with peptides and
proteins at the analytical- and laboratory-scale preparative levels. Unique aspects of
peptide and protein structure, unexploited by methods other than hydrophobicity, drive
the highly selective binding to (and elution from) the reversed-phase matrix, through
multiple weak vander waals-type interactions. The resolving power of this technique is
remarkable, permitting, in many cases, total separation of nearly identical molecules.
Generally in all types o f HPLC, division of the analyte molecules is involved between
two phases within the column, viz the mobile phase and the stationary phase. The mobile
phase is typically a liquid which is passed through a column containing an organic
stationary phase that is chemically bonded to the surface of the support particles making
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up the column packing. In RP-HPLC, the stationary phase is non-polar and the mobile
phase is polar. As such, a differential migration of species takes place as the sample is
eluted through the column based upon the relative polarity of the individual analytes
themselves. A non-polar analyte will have greater affinity for the non-polar stationary
phase than it will for the relatively polar mobile phase and will be more tightly bound to
the column and vice-versa. In this mode of separation, the most polar analyte is the first
to be eluted from the column [86-88], Figure 2.3, shows the schematic of a HPLC

Pump

Pre-column

Injector

Analytical column

G u a rd c o lu m n

M obile phase

Detector

Column oven

Figure 2.3. Schematic of a HPLC system [89].

Gradient elution is usually preferred for RP-HPLC polypeptide separations.
Effectively separation of similar polypeptides can be achieved when shallow gradients
are used and where isocratic separation would be problematic. Correlation between sidechain hydrophobicity and retention time in a peptide can be problematic due to limited
interactions imposed by tertiary structures in most peptides. Peptide separations are also
sensitive to the pH of the elution buffer due to the protonation and de-protonation of the
acidic and basic side-chains. Polypeptide separation and resolution is not affected much
by the flow-rate. RP-HPLC is used for the separation of peptide fragments from
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enzymatic digests and for purification of natural and synthetic peptides. Preparative RPHPLC is frequently used to purify synthetic peptides in milligram and gram quantities
[90, 91] and used to purify micro-quantities of peptides for sequencing and purify
milligram to kilogram quantities of biotechnology-derived polypeptides for therapeutic
use [92, 93]. The hydrophobic part of a polypeptide, responsible for the separation, is
very sensitive to molecular conformation. This sensitivity of RP-HPLC to protein
conformation results in the separation of polypeptides that differ not only in the
hydrophobic part but also oxidized amino acids or in single amino acid substitutions.
Scalability of any HPLC procedure involves changing from existing columns to either
larger or smaller columns. It is often desirable to retain the same resolution and retention.
To achieve the same retention times and performance on the columns with different
geometries, flow velocities must remain constant by adjusting flow rates accordingly.
The use of different elution solvents, ion-pairing agents, buffers and gradient conditions
may also be involved.
2.2.3 Capillary Electrophoresis (CE)
The need for high-resolution separation of biopharmaceuticals and concerns about
toxic compounds in the environment paved the way for the development of capillary
electrophoresis. Michaelis separated proteins on the basis of their isoelectric point in
1909 and coined the term “electrophoresis”. The pioneering work of Hjerten [94] laid the
ground work for modem day CE analysis of various analytes. Over the last few years CE
has proved a rapid and versatile analytical technique that combines simplicity with high
reproducibility. CE can be used for the separation of a variety of analytes of different size
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and charge: simple molecules, organic and inorganic ions, peptides, proteins,
carbohydrates and nucleic acids.
The basic instrumentation consists of four parts. A narrow diameter capillary is
required for the separation, a high voltage power supply is required to drive the
separation, a detector is required to detect the presence and amount of analyte and a
safety interlock-equipped enclosure is used to protect the operator from high voltage.
Either pressure or vacuum is applied to the sample and 10 - 100 nL is injected, or an
electrical current is applied through the sample and only the charged molecules enter the
capillary. Figure 2.4, shows the schematic of a CE system
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D ete cto r

Buffer

R eserv o ir

S a m p le
Vial

Buffer
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High V oltage
P o w e r S u p p lie r

Figure 2.4. Schematic of a CE system [95].

The resulting migration of a charged particle in CE is a sum of the electrophoretic
flow, determined by the size and charge on the molecule, and the electroosmotic flow,
determined by the charge on the inner surface of the capillary. The plot of detector
response with time is generated and called an electropherogram. The flow of electrolyte,
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known as electroendosmotic flow, EOF, results in the flow of the solution along the
capillary towards the detector.
Numerous peptide applications using CE have been explored in the last decade.
Peptides, because of their fairly simple structure, show little interaction with the capillary
and show high separation efficiencies. Due to the presence of limited number of ionizable
groups in their structure, peptides are often separated at extremes of pH where all the side
chains are either protonated or deprotonated. These extremes in pH are used to separate
peptides of different length that will differ by their charge to mass ratios. The greatest
selectivity difference for acidic residues can be found in the range of pH 2 to 7, while, for
basic residues it is usually pH 8 to 10. Various studies have been done towards achieving
optimal separations [96-101] however, understanding the relationship between structure
and charge is the most direct way of optimization. Additives like organic solvents,
surfactants, and chiral selectors are used when the compounds are closely related and pH
optimization does not lead to desired resolution.
CE is a powerful analytical tool that replaces methodologies that are inherently
slow and labor intensive. Low injection volumes and rapid analysis times enable the
analysis of a large number of samples over a short period of time. The process can be
scaled up by advances in instrumentation and detection systems. As is the case with any
pharmaceutical, an antibiotic must be characterized in terms of its potency and the
presence and quantity of impurities. Additionally, any residue or metabolite that may be
present as a result of its use must be monitored. Many CE techniques have been used in
the analysis of antibiotics, addressing the various aspects of quantifying, profiling, and
monitoring. The auto-sampler tray, through which samples and buffers are injected into
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the capillary facilitates automated analysis of more than one sample one after the other.
Also, recently multiple capillary instruments have been reported which have five
capillaries, enabling the analysis of as many samples at any given time. In view of the
increasing sample complexity and the requirement for obtaining structural information
from extremely limited amounts of material, coupling CE instrumentation with mass
spectral detection offers unparalleled advantages over single parameter detection systems.
2.2.4 Nuclear Magnetic Resonance (NMR)
Nuclear magnetic resonance is a phenomenon which occurs when the nuclei of
certain atoms are immersed in a static magnetic field and exposed to a second oscillating
magnetic field. Some nuclei experience this phenomenon, and others do not, depending
upon whether they have a property called spin. An NMR structure is an atomic model
based on the interpretation o f a set of interatomic distances. NMR measurements provide
crucial evidence regarding behavior in solution and can provide structural information on
rapid time scales. Multidimensional NMR spectroscopy gained substantial power with
the advent of multi-isotope and heteronuclear techniques, which facilitate the resolution
of spectra that are tightly packed and impossible to resolve in two dimensions. Using
different isotopes (generally 14C and 15N) it is now possible to obtain a sufficient number
of constraints to define structures of peptides and proteins [102]. Kinetic behavior on a
wide variety of time scales can be studied by NMR relaxation spectra [103-106]. Solidstate NMR spectroscopy has been used to monitor the layer-by-layer (LBL) growth of
polyelectrolyte multilayers on colloidal silica. The dynamics and conformation of
polyelectrolyte multilayers comprised of the weak polycation, poly(allylamine)
hydrochloride, and the strong polyanion, poly(sodium-4-styrene sulfonate), assembled at

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

31

pH 7 and pH 10 were studied by a combination of *H and 13C NMR measurements and
the effect of adsorbed water has also been investigated [107-110]. Extension of these
studies to polypeptide multilayer films would provide us with a greater insight into the
physics of interaction of designed polypeptides in the film and would lay the foundation
of designing peptides for highly specific applications.
2.2.5 Mass Spectrometry (MS)
Ionization methods suitable for peptides include secondary ionization mass
spectrometry (SIMS) [111], electrospray ionization (ESI) [112], and matrix-assisted laser
desorption ionization (MALDI) [113]. Each of the techniques has its own advantages.
Peptide signals may be suppressed by the presence of salts, detergents, or other peptides.
In most cases, salts are removed during peptide mapping by reversed phase HPLC where
TFA is used as an ion-pairing agent. It should be remembered that all peptides from a
map must be collected and stored in polyethylene or polypropylene tubes. To get a good
signal, the peptide must be soluble and be able to migrate to the surface of the liquid
matrix where the ionization takes place. Small polar peptides tend to give poor signals,
perhaps due to surface phenomenon, and must be derivatized by esterification to
overcome this problem [114].

2.3 Film Characterization Techniques
Various tools are used to characterize polyelectrolyte multilayer films. The
emphasis here is on physical techniques. One might be also interested in chemical
properties or biofunctionality in the case of polypeptide films. Examples of such
properties include redox potential and immunogenicity more specifically related to target
applications than basic film properties. The polyelectrolyte LBL literature is too large to
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provide a comprehensive account of references however, references to papers in which
the indicated methods have been used to study polypeptide multilayer films have been
provided.
2.3.1 Quartz Crystal Microbalance (QCM)
The Quartz Crystal Microbalance (QCM) is an extremely sensitive mass sensor,
capable o f measuring mass changes in the nanogram range. QCMs are piezoelectric
devices fabricated of a thin plate of quartz with electrodes affixed to each side of the
plate. QCM crystals are used as sensors to determine mass changes as a result of
frequency changes. Frequency shift is converted to mass increment by the relation A /«
-A.m (1.83 x 108)/yf, w here/is the resonant frequency in Hz, m is the deposited mass in g,
and A is the surface area of the resonator [115]. QCM provides information on mass
change and kinetics of polyelectrolyte adsorption by way of change in resonant frequency
[116-122], The streaming potential method is used to characterize electrical properties of
a film surface. The basic principle is to measure pressure and potential difference on both
sides of a capillary [67, 71, 73, 123, 124], Figure 2.5 shows a quartz crystal resonator

Figure 2.5. Quartz crystal resonator.
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2.3.2 UV-vis Spectroscopy
UV-vis spectroscopy is a relatively cheap way to measure the optical mass of
assembled polypeptides in terms of absorbance increase per layer, or disassembled
material in terms of absorbance decrease [118,120]. For just visible spectroscopy,
ordinary glass cuvettes may be used, but ultraviolet spectroscopy requires special
cuvettes made of a ultaviolet-transparent material such as quartz. The polypeptides are
assembled from solution onto a quartz substrate for a given time. The substrate is then
rinsed, dried and placed in the path of a light beam that scans from 190-300 nm.
M olecules which absorb photons o f energy corresponding to wavelengths in the
range 190 mm to about 300 nm exhibit UV-vis absorption spectra. The peak
m axim a occur at 214 nm corresponding to the peptide bond absorbance and
absorbance from aromatic amino acids (tyrosine, tryptophan, and phenylalanine)
can be observed at 280 nm. In some cases UV spectroscopy can provide useful
information on structure in terms of position of absorbance peak maximum. Figure 2.6
shows a Jasco V-530 UV-vis spectrophotometer.

Figure 2.6. UV-vis spectrophotometer.
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2.3.3 Circular Dichroism Spectroscopy (CD)
Circular dichroism is the observed elliptical polarization of right and left
circularly polarized light produced by an optically active medium in the vicinity of its
absorption bands. Circular dichroism spectrometry (CD) enables a moderately accurate
determination of film secondary structure content, important when polypeptides are
involved [116, 118, 120-122, 125]. The far-UV CD signal is particularly sensitive to
conformation of the polypeptide backbone; different secondary structures have more
distinctive spectral signatures in CD [126], CD can provide extensive information on
secondary structures in peptides [13, 127-130] and it measures the differential absorption
of right- and left circularly polarized light. In the far-UV region of the spectrum, 180-260
nm, the signal is very sensitive to the average conformation of the polypeptide backbone
whether the peptide is in solution or in a film [131]. Figure 2.7 shows signature spectra
for various secondary structures in proteins.
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Figure 2.7. Signature spectra of different secondary structures [126].
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A set of reference spectra and some assumptions underlie spectral analysis [132],
The reference spectra generally are proteins or peptides for which the secondary structure
content is known by an independent means, for example X-ray crystallography. The basic
principle of analysis is that a CD spectrum can be regarded as a linear combination of
spectra of distinct secondary structures. By this approach one can estimate the fractional
content of a helix, (3 sheet,

turn, and random coil with considerable accuracy.

Comparison of the various physical methods would suggest that CD is the most
informative one for obtaining information on the conformation of polymers in a
polyelectrolyte thin film. CD analysis of polypeptide films [118,121,122,133] has yielded
the most detailed experiment-based view to date of polymer structure in a polyelectrolyte
multilayer film than FTIR.
2.3.4 Ellipsometrv
Ellipsometry is an optical technique that relies on the optical physics of the
stratified media. Excellent treatments of the subject exist and ellipsometry is one of the
few techniques that can accurately monitor thin-film processes while they occur, yielding
both fundamental properties and process information about the system under
measurement. In addition it is possible to use feedback to affect control of thickness,
composition, and temperature, for example, which are process related parameters. If
linearly polarized light o f a known orientation is reflected at oblique incidence from a
surface then the reflected light is elliptically polarized.
An ellipsometer measures the changes in the polarization state of light when it is
reflected from a sample. If the sample undergoes a change, for example a thin film on the
surface changes its thickness, then its reflection properties will also change. Measuring
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these changes in the reflection properties can allow us to deduce the actual change in the
film's thickness [72,118,125,134,135], The amount of material adsorbed can be calculated
from the thickness and refractive index. Figure 2.8 shows a schematic of an ellipsometer

s
Figure 2.8. Schematic diagram of a nulling ellipsometer.

2.3.5 Atomic Force Microscopy (AFM1
The atomic force microscope (AFM) is a very high-resolution type of scanning
probe microscope. The AFM was invented by Binnig, Quate and Gerber in 1985, and is
one of the foremost tools for the manipulation of matter at the nanoscale. A cantilever
scans the solid surface and the deflection of the cantilever is detected by the reflection of
a laser beam. The primary modes of operation are contact mode, non-contact mode, and
dynamic contact mode. In the contact mode operation, the force between the tip and the
surface is kept constant during scanning by maintaining a constant deflection. In the noncontact mode, the cantilever is externally oscillated at or close to its resonance frequency.
The oscillation is modified by the tip-sample interaction forces; these changes in
oscillation with respect to the external reference oscillation provide information about the
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sample's characteristics [136], In simple terms, AFM is similar in principle to early
record players, where the movement of the sharp needle in the groove reproduced the
sound. Because the AFM relies on actual contact to sense the nature of the sample
surface, it can be used to non-conducting materials like biological molecules, organic
material, biopolymers, and living cells. Figure 2.9 shows a schematic of an AFM

Detector and feedback
electronics
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Cantilever & Tip
;~) Sam ple Surface
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Figure 2.9. Schematic of AFM

The biggest advantage of AFM is that most samples can be investigated in their
natural state including aqueous environments. AFM has thus become a well established
and valuable tool in three-dimensional topographical imaging of biopolymers [137-142]
and has been used to characterize film surface morphology, roughness, and thickness of
polypeptide multilayer films [73,118,120,123-125,143,144],
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2.4

Computational Approach

Computer-based approaches for the development of polyelectrolyte multilayer
thin film technology have already appeared in the scientific literature [145-152].
Important for commercialization of polypeptide multilayer films, MD simulations can
also be used to study some aspects of the peptide design process. Such analysis will
provide insight on polyelectrolyte complexation and the relationship between
electrostatic interactions, hydrophobic interactions, hydrogen bond formation, secondary
structure, and film stability. Simulations could also help to understand the internal
structure of an LBL film. A series of MD simulations on designed peptides have been
done to test the role of differences in amino acid sequence on aspects of peptide
interaction [133]. The initial structure in each case was a parallel or anti-parallel /3 sheet
with standard bond angles, selected on the basis of the known secondary structure content
of polypeptide films. The results show that primary structure can have a major impact on
the interaction energy in general and the number of hydrogen bonds between strands in
particular, especially when the charge density is high and the electrostatic interactions
between side chains extensive. These conclusions are consistent with corresponding
experimental studies [133].
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CHAPTER 3

ANTI-MICROBIAL POLYPEPTIDE MULTILAYER LILMS *

3.1 Introduction
A multilayer coating (or film) of nanometer-thick layers with antimicrobial
properties can be made by sequential adsorption of oppositely charged polyelectrolytes
on a solid support. The method is known as layer-by-layer assembly (LBL). No special
apparatus is required for LBL and nanofilms can be prepared under mild, physiological
conditions, formed by the nano-scale fabrication process known as electrostatic LBL [15,
152], The method involves the sequential adsorption of oppositely-charged species onto
a solid support. Polyelectrolyte multilayer film layers have a thickness on the order of 1
nm per layer, the precise value depending on the linear charge density and molecular
weight of the adsorbing polymers, extent of film hydration, and ionic strength. The basic
character of LBL, however, depends neither on the surface area of the support nor its
shape, just the charge properties of the surface and the assembling species.
Polyelectrolyte multilayer films and coatings can feature a variety of useful properties,
for example, biofunctionality, as when a macromolecule with specific biochemical
properties is incorporated [47], The layering process in LBL is repetitive and has been
automated, important for commercial prospects of applications of the technology.

39
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Films and coatings with antimicrobial properties are being developed for a variety
of purposes. For example, ductwork coatings are used to improve indoor air quality
[153], Colonization of bacteria is inhibited by the incorporation of anti-bactericidal
agents in the coatings and the release of the bactericides over time. Antimicrobial films
have been investigated in medical research as a means of accelerating wound and scar
healing and lowering infections due to implanted devices [154-156]. Antimicrobials have
been incorporated into textiles [157]. Coating a food with an edible antimicrobial
material could serve a variety of purposes, such as preventing physical, chemical, or
biological degradation of food items while preserving moisture, flavor, and quality [158161].
Edible and biodegradable food coatings are attractive because they can reduce
packaging costs and municipal waste [162],

Numerous chemicals that could be

incorporated into a thin film to inhibit microbial biofouling, however, will also abrogate
edibility.

A need exists therefore to develop coatings that both inhibit microbial

contamination and maintain edibility [163]. Incorporation of antibacterial enzymes into
biodegradable films seems more advantageous than incorporation of antimicrobials into
plastic wrappers, because most biodegradable films are edible and they can be formed
under mild conditions [164]. The antimicrobial enzyme incorporated into the polypeptide
thin films studied here is HEWL.

This enzyme is edible and widely used for food

preservation.
The natural biopolymers known as peptides and proteins constitute roughly half
of the dry mass of an organism. Peptides and proteins can be purified from a plant or
animal source for use as a raw material for the production of biocompatible films,
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coatings, and microcapsules [165]. Structural and functional properties of proteins have
been exploited in the development of thin films for diverse applications, for example,
biomedical implants, biosensors, chromatographic membrane separations, and food
coatings [166].

Edible films prepared from various proteins have attracted much

attention for use in food protection and preservation as they present a number of
advantages over synthetic films, including favorable degradability and environmental
characteristics [167]. The thin films studied here are polypeptide multilayer films [142]
consisting of PLGA, a readily available synthetic homopolypeptide, and HEWL, a readily
available enzyme that is straightforward to purify by virtue of its high net charge at
mildly acidic pH. Given the generality of LBL, the method is appropriate for all
antibacterial compounds which have a suitable surface charge at the pH of film assembly.
The incorporation of antibacterial proteins or polypeptides in multilayer films represents
a promising area for development in biomaterials and biotechnology. In this chapter a
multilayer nanofilm in which one of the constituent species is an antimicrobial protein
have been fabricated and studied for activity and sustained release. The basic approach
was to fabricate the films using LBL and study the release of the antimicrobial protein
over time and under various conditions. An attempt has also been made to quantify the
amount of protein released over time and all methods were developed empirically for
further work.
Earlier work has shown that antimicrobial peptides [168] or silver nanoparticles
[169] can be incorporated into a multilayer film, conferring antimicrobial functionality.
It seemed to us that antimicrobial proteins or peptides could be combined with
polypeptide LBL to explore the development of novel biodegradable and edible food
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coatings or packaging techniques, or a new generation of coatings for implant devices.
Here, we show that multilayer films in which HEWL is incorporated by simple
electrostatic attraction will inhibit M. luteus proliferation in the surrounding medium.
The results indicate that HEWL molecules are released from films over time and that a
proportion of the HEWL molecules incorporated into the films retain functionality. The
results suggest that similar films could be developed for various practical applications
where microbial biofouling is a concern.

3.2 Materials and Methods
PLGA (13 kDa), HEWL, Luria-Bertani (LB) broth, M. luteus (lyophilized), 4methylumbelliferyl N-acetyl-chitotrioside ((GlcNAc)3-MeU), monobasic and dibasic
sodium phosphate, sodium acetate, ethylenediaminetetraacetic acid (EDTA), sodium
chloride and sodium azide were from Sigma-Aldrich (USA). Glycerol was from Pfaltz
and Bauer (USA). Tris(hydroxymethyl)aminomethane (Tris) and glycine were from ICN
Biomedicals (USA). All other chemicals were from Sigma-Aldrich. 18.2 M_-cm water
(SIMS60000 water purifier, Millipore, USA) was used in all experiments. In additional,
all buffers were filtered at 0.45 jam before use, limiting bacterial contamination. LB broth
was prepared by dissolving 20.6 g of broth mix in 1 1 water and then autoclaving.
Solutions for film assembly were prepared by dissolving PLGA in 10 mM Tris, 75 mM
NaCl, pH 7.4 to a final concentration of 1 mg/ml, and HEWL to 2 mg/ml in the same
buffer.
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3.2.1 LBL
Films were fabricated by repetitive alternate adsorption of PLGA and of HEWL
from aqueous solution with an intermediate rinsing step in water. Figure 1 presents a
schematic illustration of LBL. Each cycle of the assembly procedure consisted of
immersing the substrate in HEWL solution for 15 min, rinsing with water, immersing the
substrate in PLGA solution and rinsing with water. The process was repeated until 3, 7,
11, 15, or 21 layers were adsorbed; in all cases HEWL was deposited in the final layer.
Where indicated, films were dried with nitrogen gas prior to adsorption of the oppositely
charged species. Figure 3.1 shows the schematic assembly of HEWL (spheres) and
PLGA (irregularly structured polymers)
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Figure 3.1. Schematic of HEWL and PLGA assembly by LBL.

3.2.2 Quartz Crystal Microbalance (OCM)
PLGA/HEWL films were assembled at room temperature on silver-coated
resonators of 9 MHz nominal resonant frequency (Sanwa Tsusho, Japan). Resonator
surfaces were cleaned with a solution of equal parts of water, 1 M NaOH and 70%
ethanol. Resonant frequency was determined with an Agilent 53131A 225 MHz universal
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counter (USA) after deposition of each layer of PLGA or HEWL. The film was always
dried before measurement, enabling frequency shift to be converted to mass increment
[115] by the relation J « - jyi (1.83 x 108)/A, w h ere/is the resonant frequency in Hz, m
is the deposited mass in g and A is the surface area of the resonator (0.16 cm2 per side).
Five sets of 2-ml assembly solutions of PLGA and HEWL were prepared as described
above. The first set had 0.1% azide in each, the second 2 mM EDTA in each, and the
others 5, 15, or 25% (w/v) glycerol in each. Azide and EDTA are known antimicrobials.
Glycerol, a plasticizer, reduces film brittleness.
3.2.3 UV Spectroscopy
Quartz cover slips (ElectronMicroscopy Sciences, USA), 7.5 cm><2.5 cmxO.l mm
in size, were cut into rectangular pieces of 1.25 cm x 2.5 cm, cleaned for 30 min in 1%
sodium dodecylsulfate at 80°C with agitation and washed for 2 h with 1 M
Na0H/C2H50H (60:40, v/v) and overnight with H2S04/H202 (75:25, v/v). The slides
were then rinsed extensively and stored in ultra-pure water until film assembly. The
substrate was glass instead o f quartz in cases not requiring UV analysis. In all cases the
films were dried with nitrogen gas before spectral characterization.
3.2.4 Bacterial Culture
The well-studied model microbe M. luteus was cultured in LB broth overnight at
30°C and stirring at 200 rpm after sterilization of the medium by autoclaving. In a typical
HEWL activity experiment, log phase culture was diluted to an initial optical density
(OD) at 600 nm o f 0.005. All OD measurements were taken with a Jasco V-530
spectrophotometer (Japan) outfitted with a constant temperature cell holder. A decrease
in concentration of bacteria in the liquid culture surrounding each film was measured as a
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decrease in OD at 600 nm. The OD of M. luteus suspension decreases in the presence of
active HEWL due to decreased strength of the cell wall, lysis and the reduced ability of
cell membranes and cellular debris to scatter light at 600 nm relative to intact cells.
3.2.5 Activity of HEWL Released from Films
The activity of HEWL in the liquid medium surrounding PLGA/HEWL films of
0, 3, 7, 11, 15, or 21 layers was quantified by M. luteus assays or by hydrolysis the
HEWL of 4-methylumbelliferyl N-acetyl-chitotrioside ((GlcNAc)3-MeU), a fluorescent
substrate analog [170]. In the bactericidal assays, the relative activity of HEWL released
by PLGA/HEWL films into the surrounding liquid medium was determined by change of
OD. Each assay was done by mixing 0.25 ml of the buffer in which the PLGA/HEWL
film was immersed with 2.75 ml M. luteus cell suspension (0.25 mg/ml in 50 mM sodium
phosphate, pH 7.0). There was continuous stirring at 200 rpm and, and the temperature
was held at 30°C. Change in OD 600 nm was determined after 10 min.
In (GlcNAc)3-MeU assays, labeled saccharide was dissolved to a known
concentration in 0.1 M sodium acetate, 0.5 M NaCl (pH 3.8). The anionic form of MeU is
fluorescent, and equilibrium disfavors anion formation at the pH of the assay. In each
case the reaction mixture consisted of 100 [A liquid medium in which the film was
immersed, 100 /rl saccharide solution and 300 /d water. The pH of the mixture was 4.5.
The enzymatic reaction mixtures were incubated at 42°C for 1 h. Then the reactions were
stopped, and released MeU was converted to the anionic form by addition of an equal
volume of glycine buffer at pH 12. MeU concentration was quantified by measurement of
fluorescence intensity at 465 nm. The excitation wavelength was 360 nm. A standard
curve shown in Figure 3.2 was prepared to quantify the amount of released HEWL.
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Figure 3.2. Standard curve for HEWL activity assays.

3.2.6 Activity o f HEWL Retained in Films
The activity of PLGA/HEWL films was determined after immersing film-coated
slides in Petri dishes containing 4 ml 0.25 mg/ml M. luteus suspension in 50 mM sodium
phosphate (pH 7.0), incubating at 30°C and stirring at 200 rpm. Relative activity was
measured as change in OD at 600 nm.
3.2.7 Stability of Bioactive Films
The longevity of anti -Micrococcus activity of PLGA/HEWL films was tested
after immersion o f the films in 50 mM phosphate (pH 7.0) at 4°C for 1 month or
lyophilization and storage at 4°C for 1 month. The liquid medium surrounding the films
was assayed for HEWL activity after 14 h incubation at 30°C and 200 rpm continuous
stirring as described above. 0.01 mg/ml HEWL solution was kept in 50 mM phosphate
(pH 7.0) at 4°C for 1 month as a control on loss of activity due to spontaneous
inactivation o f enzyme molecules by any mechanism.
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3.3

Results and Discussion

15-layer films were fabricated on QCM resonators to study mass deposition in
PLGA/HEWL film assembly. Film mass increment, however, was positive for HEWL
deposition and negative for PLGA as shown in Figure 3.3.
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Figure 3.3. PLGA/HEWL multilayer film assembly monitored by QCM.

The data suggest that a portion of film material returned to solution during PLGA
adsorption steps, possibly by formation of a soluble complex between PLGA molecules
and previously adsorbed HEWL molecules. The loss of HEWL on adsorption of PLGA
suggests that HEWL is unlikely to be uniformly oriented on the film surface: some
molecules will be more strongly adsorbed than others, owing to the non-uniformity of
substrate surface charge density, the complex nature of the molecular surface of HEWL
and deformation of HEWL structure on adsorption. Highly-charged and disordered
polypeptides tend to adsorb on a surface more effectively than HEWL and, probably,
proteins in general [120]. The results show an overall linear increase in film mass with
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number of layers deposited because frequency shift is proportional to mass increment for
dry films [115] (Figure 3.4).
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Figure 3.4. PLGA/HEWL multilayer film assembly monitored by QCM (bilayer).

Nevertheless, the data show that enough of the adsorbed HEWL molecules remain
bound to the film surface during PLGA deposition for peptide adsorption to occur and be
sufficient for the subsequent adsorption of another layer of HEWL. The conditions under
which the frequency shift measurements were made, i.e., dry films, enable quantitative
statements to be made with regard to mass deposited on and mass lost during the
assembly process. The total mass of HEWL deposited in 15 layers was about 1.3 fig. This
is the difference between the cumulative mass gained during deposition steps and the
cumulative mass lost during PLGA deposition steps. The surface density of HEWL was
about 4.1 jttg/cm2. This result suggests that approximately 22 fxg of HEWL were deposited
in 15-layer films on a quartz or glass slide of surface area approx. 7 cm .
Glycerol is a plasticizer in edible films and food coatings [171], and it stabilizes
the folded protein structure in aqueous solution [172], EDTA, a chelating agent that
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enhances the antimicrobial activity of bacteriocins, and is useful for broadening the
spectrum of other antimicrobials [173]. As shown in Figure 3.4 neither glycerol nor
EDTA substantially altered multilayer film assembly under the conditions studied here;
film assembly occurred in both cases and the additives had no practical effect on the
general character of film assembly.
Data on PLGA/HEWL film assembly have also been obtained by UV absorbance.
The films were prepared on quartz slides; glass is largely opaque to UV. The data show
that the amount of material deposited is not a strictly linear function of the number of
layers as seen in Figure 3.5. The consistency of film preparation on different surfaces is
relevant to the scope of applicability of the basic methodology outlined here. The amount
of material adsorbed onto the surface depended to some extent on whether the film was
dried between assembly steps, albeit little. The data suggest that intermediate drying steps
are unnecessary for film fabrication, potentially important for manufacturing.
0.40
100

0.35

—o— Dry film
—• — W et film

0.30

ao)
c
to
.o
o
tf>
<

0.25

0.20

_Q

0.15
0.10
Number of layers

0.05
0.00
200

220

240

260

280

300

W a v e le n g th (n m )

Figure 3.5. PLGA/HEWL film assembly monitored by UV spectroscopy.
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In any case, multilayer film assembly of a protein and peptide is a more complex
process than assembly of two disordered polypeptides, given the complex structure and
charge properties of the folded state of a protein and the more flexible nature of a largely
unstmctured and uniformly charged peptide [119]. Nevertheless, in general the assembly
behavior obtained by UV absorbance corroborates that by QCM.
Enzyme is released from PLGA/HEWL films over time into the surrounding
aqueous environment. Some of the enzyme retained in the film is active. Both regions of
HEWL activity have been characterized in this work. The results indicate that the greater
the amount of HEWL deposited, the greater the amount of HEWL released in a given
interval of time. Lysis of M. luteus cells increased as the number of film layers increased.
This implies that the amount of HEWL that leaches out of a film depends on the number
of layers o f HEWL and, therefore, on the amount of HEWL in the film. The antimicrobial
activity of PLGA/HEWL films in liquid culture medium is illustrated in Figure 3.6.
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Figure 3.6. Activity o f PLGA/HEWL films against M. luteus.
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A higher concentration of active HEWL in solution will result in a greater
decrease in OD at 600 nm in a given time interval, because a greater proportion of cells
are ruptured and fewer particles are available to scatter light effectively at 600 nm [174],
HEWL activity in the aqueous medium surrounding PLGA/HEWL-coated slides of a
certain number of layers was studied by fabricating fresh films and freeze drying, or by
fabricating and incubating in buffer for 1 month. In films immersed in buffer, a large
percentage o f adsorbed HEWL is released into the surrounding buffer during 1 month at
4 °C. Antibacterial activity increased with an increase in the number of layers. In
lyophilized films, HEWL remained active and was released on immersion in an aqueous
medium. The activity of lyophilized films was comparable to that of freshly prepared
ones. The total activity of HEWL in films after immersion in an aqueous medium will
probably be lower than that of a lyophilized film or a freshly prepared film as shown in
Figure 3.7.
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Figure 3.7. Relative antimicrobial activity of PLGA/HEWL films under different
conditions.
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About 20% activity in control samples consisting of HEWL in aqueous solution
was lost in the course of 1 month. There is relatively little difference in the ability of the
films to kill M. luteus after the initial leaching period. This suggests that the bacteria are
killed either by a similar quantity of HEWL immobilized on the film surface, or by an
approximately constant rate of release of HEWL from the film. In any case, it is
somewhat surprising that the 3-layer film is about has about the same bactericidal
effectiveness as the 21-layer film under the conditions studied here. The activity of the
films (due to immobilized HEWL) in bacterial culture medium after a 14-h period of
leaching of HEWL into buffer is shown in Figure 3.8. There is little difference in the
bactericidal effectiveness of fresh and lyophilized films, whereas films stored in buffer
for clearly do lose activity over the course of a month.
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Figure 3.8. Anti-microbial activity of PLGA/HEWL multilayer films of different
thickness after 14 h of immersion in phosphate buffer at 30°C with continuous stirring at
200 rpm.
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The OD at 600 nm after 100 min incubation with M. luteus suspension of freshly
prepared films, films stored for 1 month in buffer, and lyophilized films is shown in
Figure 3.9.
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Figure 3.9. Effect of PLGA/HEWL films o n M luteus culture.

Taken together, these experiments show that the polypeptide multilayer films both
release HEWL into the surrounding medium and retain HEWL activity over an extended
period of time. HEWL activity is approximately independent of the number of layers and
also independent of whether the films are fresh or lyophilized. HEWL either becomes
inactivated over time in films stored in buffer or it leaches out of the films. The amount
of HEWL released is a roughly linear function of the number of film layers. The data
indicate that the amount o f HEWL in the surrounding medium of a 15-layer film was
approx. 9 fig, or about 2/5 of the amount originally adsorbed on the slide. The quantity of
HEWL released from PLGA/HEWL films is shown in Fig. 6. The HEWL concentration
ranged from 0 to 0.4 pM, as determined by comparison of the fluorescence of samples
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taken from surrounding aqueous environment as shown in Figure. 3.10 with a standard
curve (Figure. 3.2).
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Figure 3.10. Amount of HEWL released from film-coated slides into the surrounding
buffer.

Notable natural antimicrobial peptides and proteins, known collectively as
bacteriocins, are colicin, nisin, pediocin, reutrin and lysozyme. As an enzyme that is
widely distributed in animals,

including humans

[175], lysozyme hydrolyzes

preferentially the /3-1,4 glycosidic linkage between N-acetylmuramic acid and Nacetylglucosamine. This sugar occurs in the mucopeptide cell wall structure of certain
microorganisms, for example, M. luteus [176], the model organism chosen for the present
work. HEWL is known to be active against various microbes of concern in food safety,
notably, Listeria monocytogenes and certain strains of Clostridium botulinum [177].
When added to EDTA, HEWL has an antimicrobial spectrum that extends to Gramnegative bacteria [173], HEWL-EDTA is a common combination of antimicrobial agents
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in packaging applications [178], HEWL has been efficiently incorporated into zein films
as a preservative; in concert with EDTA, HEWL inhibits growth of Escherichia coli in
such films [179].
Retention or slow release of an antimicrobial is essential for extending
antimicrobial activity over time and protecting against microbial colonization. Some of
the experiments on PLGA/HEWL films described here were done after an initial release
of material during a given time interval. The measured activity of the films is not a
reflection of their HEWL content per se, but of the activity of HEWL released from the
film and, in some cases, of HEWL present at the film-liquid interface. PLGA/HEWL
films that had been pre-conditioned by immersion in buffer for 14 h showed no pattern of
increase or decrease of bacterial growth with respect to number of film layers (Fig. 5,
bottom); antimicrobial activity was about the same in each case. The net decrease of
intact bacteria in solution due to retained HEWL in the films also did not depend
significantly on the number of layers (Fig. 5, continued). This suggests that about the
same amount of active HEWL was present on the film surface or was released from the
film per unit time in each case. It would appear that the amount of HEWL on a film
surface or lost from the film to the surrounding liquid medium reaches a plateau for a
given surface area, irrespective of the number of final layers in the film. The film
longevity experiments show that the PLGA/HEWL films are stable and active after
lyophilization. Storing the films in an aqueous medium, by contrast, results in the slow
release of enzyme into the surrounding environment.
The net charge of a multilayer film must be zero by the condition of
electroneutrality. The charge of one polyelectrolyte is compensated by the charge of the
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other and small counter-ions. The release of HEWL from the film, therefore, can be
attributed to soluble complex formation with PLGA and the replacement of HEWL
molecules by counter-ions from the bulk solution. The concentration of HEWL in
solution is in the micromolar range, whereas the concentration of counter-ions is 1000times greater. The QCM data are consistent with a soluble complex model. The charge
per molecule of HEWL at neutral pH is around 7, whereas that on the average PLGA
molecule is over 100 electronic charges. Therefore, there is a large net negative charge on
a 1:1 complex of PLGA and HEWL, making it highly soluble in water. The release of
HEWL from films can also be attributed to some extent to the concentration gradient of
HEWL between the surrounding buffer and the film. Further research could reveal ways
of achieving greater control over HEWL release or retention properties, important for
commercialization of the antimicrobial polypeptide multilayer film technology.
There is considerable potential in the development of antimicrobial coatings for a
broad range of purposes. Bacteriocins, including HEWL and various antimicrobial
peptides, have become an increasingly important class of molecules in medicinal
chemistry and physiology [82], Multiple mechanisms for a single bacteriocin are
possible, but each antimicrobial is thought to have a unique mechanism of action with
respect to specific microorganism. Bacteriocin structure could be engineered to optimize
solubility, stability to proteolysis, and suitability for polypeptide multilayer film
assembly.
Peptides are of considerable and growing interest in multilayer thin film
fabrication, particularly in applications where biodegradability and edibility are key
design concerns. The character of polypeptide assembly in a multilayer context depends
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on pH and ionic strength, as linear charge density and secondary structure content depend
on these variables [116]. Polypeptide multilayer film roughness and density depend on
pH [125] and on polypeptide sequence [180]; this could be important for applications of
the technology [152], Polypeptide films can be reversibly stabilized by disulfide bond
formation between cysteine residues [117, 121], possibly useful for controlling the
release of incorporated or encapsulated material [181,182],

3.4 Conclusions
The present work was aimed at assessing whether polypeptide multilayer
nanofilms with specific antimicrobial properties could be prepared by incorporation of a
known antimicrobial agent in the film structure, in this case the edible protein hen egg
white lysozyme (HEWL). An advantage of LBL in this context is that the nanofilm is
fabricated directly on the surface of interest, eliminating the need to incorporate the
antimicrobial in other packaging materials. Here, nanofilms were made of poly(Lglutamic acid) (PLGA), which is highly negatively charged in the mildly acidic pH range,
and HEWL, which has a high net positive charge at acidic pH. It has been shown that
PLGA/HEWL nanofilms inhibit growth of the model microbe Microccocus luteus in the
surrounding liquid medium. The difference in activity of wet and dried films is a key
component in selecting a particular species for assembly. The amount of HEWL released
from PLGA/HEWL films depends on the number of HEWL layers and therefore on the
total quantity of HEWL in the films. Potential applications of such films include
strategies for food preservation and coatings for implant devices. Antimicrobial activity
can be conferred not only by proteins and peptides but also other charged species like
nanoparticles, and small drug molecules. The difference in the assembly behavior and
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activity over time can be different depending on the type of antimicrobial agent used.
Thus, one can gather from the experimental data presented here that the same behavior is
not warranted while working with other compounds. This initial study provides a sketch
of the scope for further development of LBL in the area of antimicrobial polypeptide
multilayer films.
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CHAPTER 4

CELL CULTURE POLYPEPTIDE MULTILAYER FILMS

4.1 Introduction
A large number of synthetic polymeric materials are available for various medical
applications and tissue engineering matrices. However, reduced unspecific protein
adsorption, enhancement of adsorption of specific proteins, and immobilization of cell
recognition motives are approaches to improve biomaterials [183-191]. The extracellular
matrix (ECM) consists o f various proteins secreted by cells: fibronectin, laminin,
vitronectin, and collagen [192] so early researchers coated materials with these proteins
[193-197]. However, tedious purification, undesirable immune response, increased
infection risks, stochastic orientation on the surface, and susceptibility to proteolysis
degradation are some serious disadvantages. These disadvantages can be overcome by
using short peptides that incorporate cell recognition motifs. The extracellular matrix
(ECM) proteins normally contain many different cell recognition motives, whereas small
peptides represent only one single motif. This feature enables them to address one
particular type of cell adhesion receptors. Attachment of a cell to the ECM determines
cell shape and maintains cell function and tissue integrity. The nature of a cell’s physical
contacts with its surroundings depends on the stability, organization, and composition of
the ECM. Cell attachment is mediated by

59

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

60

transmembrane heterodimeric protein receptors called integrins. The process of integrin
mediated cell adhesion has four partly overlapping events: cell attachment, cell
spreading, organization of actin cytoskeleton, and formation of focal adhesions. In tissue
engineering,

substrate

or

scaffold

requirements

include

biocompatibility,

biodegradability, cell adhesion, and sufficient mechanical strength to withstand long-term
cell culture in vitro.

4.2

RGD Motifs and Cell Adhesion

The RGD (R:Arginine, G:Glycine, D:Aspartic acid) sequence is by far the most
effective and often employed peptide sequence for stimulated cell adhesion on synthetic
surfaces. Since RGD peptides have been found to promote cell adhesion in 1984 [198]
numerous materials have been RGD functionalized for academic or medical purposes and
an excellent review of the subject exists [199]. Apart from RGD other important cell
adhesion motifs have been identified. Therefore, RGD sequence is not the “universal cell
recognition m otif’, but it is unique with respect to its broad distribution and usage. The
conformation of the RGD containing loop and its flanking amino acids in the respective
proteins are mainly responsible for their different integrin affinity [200]. Formation of
focal adhesions only occurs if the ligands withstand the cells contractile forces, hence
stable linking of RGD peptides to a surface is essential to promote strong cell adhesion
[201-203]. These forces can redistribute weakly adsorbed ligands on a surface, which
leads to only weak fibrillar adhesions [204-206]. Furthermore cells can move mobile
integrin ligands by internalization [207, 208]. Simple adsorption of small RGD peptides
only leads to poor cell attachment [209-214]. RGD peptides can be covalently attached to
the polymer, e.g. via functional groups like hydroxyl-, amino-, or carboxyl groups to
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provide a stable linking. Because many polymers do not have functional groups on their
surface, these have to be introduced by blending, co-polymerization, networks, chemical
and physical treatment, and immobilization [199].
RGD sequence is found to be an “active modulator of cell adhesion”, and is
recognized by 8 to 12 of the 20 known integrins, a class of transmembrane cell surface
receptors. While peptides and proteins containing the RGD cell attachment site inhibit
cell adhesion in solution, they in fact promote cell adhesion when covalently attached to a
surface as shown in Figure 4.1.

surface

spread cell

fr- smvival, proliferation

!

mtegrin

detached, round cell — ► apoptosis
Figure 4.1. Opposite effects of integrin ligands. Immobilized ligands act as agonists of
the ECM, leading to cell adhesion and cell survival, while non-immobilized ligands act as
antagonists, leading to cell detachment, a round cell shape, and apoptosis [199],

Cell adhesion blocking of RGD site has potential applications in combating
pathological conditions such as metastasis, thrombosis, and angiogenesis. RGDcontaining peptides and proteins can initiate cell signaling and influence many diseases
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such as tumors, thrombosis, osteoporosis, and cancer. This property of the RGD motif
makes it a viable target in drug delivery, and makes it a “prototype adhesion signal” in
“cell adhesion biology” [215], RGD sequence is found in several proteins of the
extracellular matrix (ECM), blood, and cell surfaces. Fibronectin [216-218], fibrinogen
[219, 220], vitronectin [218], von Willebrand factor [220], thrombospondin, laminin
[221], and some collagens, etc. - all these proteins contain RGD cell attachment sites
[222, 223]. Integrins are transmembrane receptors that recognize spatially restricted
extracellular ligands and play a significant role in mediating cell-cell and cell-matrix
adhesion. These ligands include the RGD site in proteins and/or peptides, and bind to
them selectively. Cell attachment site such as RGD motif, together with the
corresponding integrin receptors, serve as a recognition system for cell adhesion.
Integrins are heterodimeric proteins, i.e. they have two different subunits, a and b, each of
which contains potential binding sites for the ligand contributes to ligand specificity
[215], Both a and b subunits of integrins have ligand binding sites is in close vicinity of
divalent cation-binding sites [224], RGD binding to integrin has found to cause
“extrusion o f divalent cations from the integrin” [225]. In most cell attachment sites
including RGD, aspartic acid (or glutamic acid) appears to be the most significant
contributing factor, as Asp (or Glu) is a potential contributor of divalent cation-binding.
RGD-integrin interaction is important in biological processes like morphogenesis,
tissue remodeling [226], and pathological pathways. The exact sequence R-G-D is
important, and replacement of any of the three amino acids with any other similar amino
acids (such as lysine for arginine, glutamic acid for aspartic acid, or alanine for glycine)
affects the peptide attachment activity [255]. Moreover, activity can be influenced by the
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optical conformation of the amino acids; while replacement of L-arginine in RGD with
D-arginine will not affect the activity, replacement of L-aspartic acid will D-aspartic acid
will deactivate the RGD site’s cell attachment capabilities [223]. Other factors that affect
the RGD site activity include the availability of the tripeptide motif near the surface of
the protein or peptide, retro-inversion [228], and the amino acid sequence in the vicinity
of the RGD sequence [223]. Amino acid residues on the C-terminal of the RGD peptides
seem to have more influence on the integrin affinity and binding than those on the Nterminal [243]. Affinity and effectiveness of RGD-containing peptides is also influenced
by charge distribution of these peptides [229].
Structure of RGD peptides significantly influences the cell adhesion and
inhibitory activities of these peptides [229, 230]. RGD peptides exist as cyclic or linear
structures. In solution, short RGD peptides tend to take a secondary structure called the /3tum [231]. It has been noticed in some cases that the rigidity of RGD, or the lack of it,
may increase affinity towards a particular integrin. Larger RGD peptides are more rigid
than shorter ones, and the rigidity and or the size of the peptides can influence the affinity
to particular integrins. Cyclic RGD peptides have restricted conformation, which can in
turn enhance integrin affinity [223], The presence of Asp residue in RGD sequence
induces chemical degradation that contributes to loss of biological activity [232], Cyclic
forms are found to be more stable due to the side chain orientation of aspartic acid and
arginine residues. In platelet aggregation inhibition, cyclic peptides have proved more
efficient than linear peptides [229].
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4.3

Cell Attachment to LBL Films

A number of studies have focused on modification of surfaces using LBL with
different materials to control cell attachment behavior. Analogous to proteins, cell
adhesion occurs on LBL films terminated with positively charged polyelectrolytes [71,
233], Surfaces can be rendered cytophilic or cytophobic depending on the materials used
and the intrinsic structure of the LBL film [234, 235]. Modification has been achieved by
using polyelectrolytes in conjunction with other materials like polypeptides [236],
polysaccharides [237], proteins [238], hyaluronic acid [239, 240], carbon nanotubes
[241], and nanoparticles [242]. Some researchers have investigated the positioning of
cell growth on surfaces by depositing cytophilic or cytophobic LBL films to improve or
prevent cell adhesion at desired positions [243-246]. The versatility of the LBL technique
also allows modification of surfaces with any geometry which has led to the development
of 3D scaffolds for cell adhesion and growth [247-249]. LBL coatings have also been
used to alter the cytotoxicity of certain substrates [250], More recently, it was shown that
cells can be deposited on polypeptide multilayer films fabricated from poly-(Llysine)/poly-(L-glutamic acid) (PLL/PLGA) [71, 144] and poly-(L-lysine)/Hyaluronic
acid (PLL/HA) [251, 252] and grown for several days in culture.

4.4

Peptide Design Rationale

The design of any specific peptide depends on the use for which it is intended and
the synthetic considerations. The present study is aimed at quantifying cellular
interactions with polypeptide multilayer films with inherent RGD motifs and other
physical characteristics. Substrates coated with designed peptides using LBL will be used
to study cell adhesion and proliferation. The peptide design has been varied to study
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different parameters such as hydrophobicity, hydrophilicity, and the presence of cell
adhesion motifs and cross-linking capability.

The influence of thickness, surface

roughness and secondary structure content on cell adhesion and growth will be studied.
Films will be fabricated using the designed peptides and physical characterization studies
will be done The designed peptide structures are shown in Table 4.1.

Table 4.1 Designed peptides for cell culture films.
Peptide

Code

KVGGKCGVKVGGKCGVKVGGKCGVKVGGKCGY

P1

EVGGECGVEVGGECGVEVGGECGVEVGGECGY

N1

KVGVKVGVKVGVKVGVKVGVKVGVKVGVKVGY

P2

EVGVEVGVEVGVEVGVEVGVEVGVEVGVEVGY

N2

KVGSKVGSKVGSKVGSKVGSKVGSKVGSKVGY

P3

EVGNEVGNEVGNEVGNEVGNEVGNEVGNEVGY

N3

KGRGDGKGKGRGDGKGKGRGDGKGKGRGDGKGKY

P4

EGRGDGEGEGRGDGEGEGRGDGEGEGRGDGEGEY

N4

Work has been done on designed polypeptides to probe the physical basis of
polyelectrolyte multilayer nanofilm growth with regard to electrostatic interactions,
hydrophobic interactions, disulfide bonds, and hydrogen bonds [253]. The same types of
interactions stabilize the folded state of proteins. Calculated molecular masses of the
designed peptides in solution at neutral pH are between 3000 Da and 3350 Da,
accounting for ionization of side chains and termini. The backbones of these polymers are
identical. The side chain of K is basic; E, acidic; V, hydrophobic, S, is a hydrogen bond
donor and N, is a hydrogen bond acceptor. The aromatic side chain of Y was for
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spectroscopic detection. K and E are ionized in solution at neutral pH. For all the peptides
electronic charge per amino acid residue at neutral pH was —0.25. The solubility of P2
and N2 in an aqueous medium is lower than that of other peptides owing to the relatively
large nonpolar surface of the valine side chain and the peptides were found to form
aggregates in solution. Peptides P4 and N4, each encode four RGD sequences in them
which is a known cell adhesion motif.

4.5

Film Fabrication and Characterization

The peptides were purchased from Celtek Bioscience (Nashville, USA) at 70%
purity (some sample heterogeneity, due apparently to nonideal monomer coupling, was
tolerated) and all other reagents were from Sigma-Aldrich and were used without further
purification. Typical nonpeptide polymer preparations in the multilayer film literature are
highly polydisperse. 18.2 MO-cm water was used in all experiments. In additional, all
buffers were filtered at 0.45 /tm before use, preventing bacterial contamination.
Lyophilized peptides were reconstituted in PBS buffer (10 mM phosphate buffer salts,
120 mM NaCl, and 2.7 mM KC1) pH 7.4 at 1 mg/mL. Multilayer nanofilms of all four
combinations o f designed peptide were fabricated on negatively charged solid supports
by layer-by-layer assembly (LBL). The magnitude of the surface charge density might be
different in case of different substrates and depends on the cleaning procedure employed.
In the first peptide adsorption step, a positively charged peptide was deposited by
immersion o f the substrate in 1 mg/mL peptide solution for 15 min. Loosely bound
polycations were removed by rinsing the substrate with deionized water, and the film was
dried with N2 gas. Then a negatively charged peptide was deposited on the initial layer,
and loosely bound polyanions were removed as before. The resulting bilayer was dried
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with N2 gas, completing the first adsorption cycle. All films were dried for
characterization ex situ.
4.5.1 UV Spectroscopy
Quartz cover slips (ElectronMicroscopy Sciences, USA), 7.5

c m x 2 .5

cmxO.l mm

in size, were cut into rectangular pieces of 1.25 cm x 2.5 cm, cleaned for 30 min in 1%
sodium dodecylsulfate at 80 °C with agitation and washed for 2 h with 1 M
Na0H/C2H50H (60:40, v/v) and overnight with piranha solution (H2S04/H202 75:25,
v/v). The slides were stored in piranha solution, and they were rinsed extensively with DI
water and dried with N 2 gas before the peptide film was assembled for UV-vis (Jasco,
USA) and Circular dichroism (Applied Photophysics, UK) characterization. In all cases
the films were dried with nitrogen gas before spectral characterization. After the UV
spectra were obtained, the films were stored in vials purged with N 2 gas and were sealed
using parafilm. The slides were stored at 4 °C until further use. The films fabricated on
silicon substrate were stored in a similar fashion.
4.5.2 Circular Dichroism Spectroscopy
CD enables determination of the structure of chiral molecules by detection of the
differential absorption of right- and left-circularly polarized light. In the far-UV region of
the spectrum, 180-260 nm, the signal is highly sensitive to the average conformation of
the polypeptide backbone. The absorbance of all the peptide solutions was adjusted to 1.5
(at 195 nm). The quartz slides used for UV-vis spectroscopy were used to determine the
secondary structure of the films by placing them in the path of light by securing the slide
on the sample holder using a piece of adhesive tape. The temperature was 25 °C. Twenty
scans o f each sample were collected in a quartz cell of 0.1 cm path length, using a
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Applied Photophysics, Chirascan spectropolarimeter (UK) with 100 mdeg sensitivity, 1
nm bandwidth, 0.2 s response time, 1 nm data pitch, andlOO nm-min-1 scanning rate. The
scans were averaged. Buffer baselines were determined with the same instrument settings
and subtracted from the respective sample spectra. Raw CD data were converted to mean
molar residue ellipticity.
4.5.3 Atomic Force Microscopy
Peptide films were built on Si wafers (N/Phos (100), resistivity 1-10 ohm-cm,
thickness 375-425 pm, diameter 100 ± 0.5 mm; Silicone Technology Corp., USA) for
evaluation of thickness by ellipsometry (Beaglehole Instruments, New Zealand) and
surface morphology by Atomic Force Microscopy (Veeco, USA). The wafers had a very
thin layer of naturally grown Si02 ( ~3 nm) on the Si surface. Wafers were cut into pieces
in a clean room, rinsed with deionized H 2 O, dried with N 2 gas, and stored in sealed dustfree vials until use. Multimode Ilia AFM (Digital Instruments/VEECO) with an Escanner (maximum scan area=14.2><14.2 pm2) was used to image the multilayer films in
air. Tapping Mode in air was conducted using silicon tips (TESP, VEECO) at different
points on the film surface and the AFM images were captured over two different area
sizes 5x5 pm and 1x 1 pm. Height images were plane-fit in the fast scan direction with no
additional filtering operation. The root mean square roughness (Rms) and average
roughness (Ra) were calculated using the Nanoscope software over 5x5 pm and lx l pm
areas.
4.5.4 Ellipsometry
The film thickness measurements were performed on a silicon wafer using a
phase-modulated ellipsometer (Beaglehole Instruments, (New Zealand) fixed at the angle
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of incidence near the Brewster angle (8 b =75°). The ellipticity, p=Im(rp/r,)| on measured
by the ellipsometer, where rp and rs are the complex reflection amplitudes for p and s
polarizations, respectively, is readily converted to film thickness using Drude equation.
The large contrast between the optical dielectric constant for the silicon wafer

( s sj

=15.07)

and the organic film provides an extremely good film thickness resolution of 0.02nm
averaged over the focused laser beam diameter of —0.25 mm. As the organic components
in the multilayer possesses only a marginal difference in their optical dielectric constants,
the film has been modeled as a slab of thickness L with a fixed dielectric constant. The
experiments were performed in air on three independent points substrate covered with the
LBL films. The substrates had a naturally grown =3 nm SiC>2 layer on the surface. The
measurements were taken at two refractive index values 1.34 and 1.6. To study the
variation of thickness with the refractive index (n), the thickness of a sample film (P3N3)
was measured at different ‘n ’ values from in the range 1.35-1.6 with an increment of
0.05.

4.6

Cell Culture Studies

For cell culture studies the polypeptide multilayer films were deposited on 12 mm
round glass slides (0.13-0.16 mm thick). Before assembly the glass slides were cleaned
and steriled using 70 % ethanol and later thoroughly rinsed using ultrapure water ( Hydro
Picopure®2 system, with a resistivity greater than 18.2 MO .cm). Polypeptide solutions
were always freshly prepared before assembly experiments. Three different types of film
coatings were prepared by depositing 15 layers of peptide and the final layer was
positive. The combinations assembled were chosen based on preliminary data for various
physical and biochemical characteristics. The peptide combinations used for cell culture
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studies are P2N2, P3N1 and P4N4. In addition to these individual peptide combinations
films were made by using precursor layers of PLL and PLGA (10 layers) and then coated
with the above-mentioned peptide combinations (5 layers). The films were sterilized
using 70% ethanol before seeding cells on to them.
4.6.1 Cell Culture
3T3 cells were maintained in Dulbecco’s Modified Eagles Medium (DMEM,
ATCC) containing 10 % calf bovine serum (CBS, ATCC) and 1 % antibiotic (PenicillinStreptomycin, GIBCO Invitrogen). Culture medium was replaced every alternate day,
and cells were allowed to grow until sufficient confluence was reached. Cells were
trypsinized (Trypsin, ATCC) and collected by centrifugation at 220g for 5 min, and
resuspended in complete media prior to counting and seeding. Substrates with coatings
were immersed in 70 % ethanol and later rinsed with Hank’s balanced salt solution
(HBSS) and placed in a 24 well plate before seeding cells on them. The cells with
substrates were then incubated at 37 ° C and a humidified environment of 5 % CO 2 and
95 % air.
4.6.2 Cell Proliferation
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was
done on the cells adherent on the multilayer films to determine cell proliferation. A
calibration curve correlating the absorbance with the number of cells was first obtained.
The cells were seeded at cell density of 7500 cells/cm2 and incubated for 72 hr with
media change on alternate days. At the end of 72 hrs the medium was removed and
substrates were transferred to a new well plate. The cells on coated substrates were later
incubated with 10 % MTT solution (ATCC) in media for 4 hrs. Incubation detergent
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(ATCC) was added and the plates were left in the dark overnight to dissolve the formazan
crystals (formed due to the interaction of MTT solution with cells). Absorbance of the
plate was measured at 570 nm, with background subtraction at 690 nm (Molecular
Devices Spectra Max), and the number of cells was determined from the calibration
curve.

4.7

Results and Discussion

The different films that were fabricated from the designed peptides are shown
below in Table 4.2. However, cell attachment studies were performed only on P2N2,
P3N1 and P4N4 and are the only combinations discussed here. These films were selected
based on their significant difference in surface morphology and physical composition.
The characterization data for all other combinations is provided in the supplementary
information section.

Table 4.2. Films formed from various peptide combinations.
P1N1

P1N2

P1N3

P1N4

P2N1

P2N2

P2N3

P2N4

P3N1

P3N2

P3N3

P3N4

P4N1

P4N2

P4N3

P4N4

Polypeptides, are weak polyelectrolytes and the pKa of ionizable groups in a
weak polyelectrolyte are sensitive to the local electronic environment. The net charge can
shift significantly from the solution value on formation of a polyelectrolyte complex or
film. The net charge on the positive and negative peptides varies considerably below pH
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4 and above pH 10 which are close to the pKa’s of glutamic acid and lysine respectively
which are the charged amino acids in the peptide sequences. At the assembly pH around
7.4 the charge density on all the peptides is approximately the same. In peptide N1 the
side chains of glutamic acid will repel those of cysteine when the latter become ionized;
otherwise the side chain of cysteine is neutral. The pKa of cysteine is around 8.9. The net
charge can also vary significantly in solution with the pH and its dependence on pH is
shown in Figure 4.2 for the various peptides used.
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Figure 4.2. Estimated peptide net charge versus pH.

The film growth was monitored by UV spectroscopy and was confirmed in
triplicate. The increase in the peptide bond absorbance indicates that material is being
deposited at every step of film assembly. The variations in the magnitude of deposition
from layer to layer cannot be precisely estimated by this technique and hence no
conclusions can be made about the physical growth properties. Nevertheless, it provides a
definite proof of film growth throughout the fabrication process. The absorbance was
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collected after every 3 layers of peptide was deposited for a total of 15 layers with
appropriate baseline correction. The data show that more material is deposited in case of
P2N2 compared to P3N1 or P4N4. This could be due to the aggregate deposition in case
of P2N2 compared to polymer deposition in the other cases. The solubility of P2 and N2
in an aqueous medium is lower than that of other peptides owing to the relatively large
number of valine residues (50%) and the nonpolar surface of the valine side chain. By
contrast, P3N1 shows more deposition than P4N4 due to the presence of valine and serine
residues in P3 and valine and cysteine residues in N 1. Peptides P4 and N4 are devoid of
any hydrophobic or polar residues and the adsorption is purely electrostatic. The UV
absorbance data in Figure 4.3 shows the increment in peptide deposition at different layer
numbers
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Figure 4.3. Peptide multilayer film assembly monitored by UV spectroscopy.
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The adsorption of a peptide onto surface depends on its charge or more
specifically its charge density. The role of molecular structure and charge on polypeptide
multilayer film assembly has been studied by Haynie et. al. [116]. The adsorption process
results in a substantial decrease in the number of conformations accessible to the peptide
molecule. The forces that inhibit the return of the adsorbed peptide back to solution are
electrostatic attraction, hydrophobic interactions, and hydrogen bonds. The weakest of
the three are the hydrogen bonds which are usually broken easily and hydrophobic
interactions are formed not due to the attractive forces between the nonpolar side chains
but due to the repulsive forces from the surrounding polar environment. The strongest
forces are the electrostatic attractions and the LBL method is based on the attractive
interaction of complementary charges which drives the process. Therefore, the type and
the amount of charged groups in a polymer can be satisfactory criteria to predict its
usefulness for the LBL technique and the polymer must bear a minimal number of
charged groups, below which the LBL procedure does not work. In particular cases,
alternative interactions may be even strong enough to allow for LBL assembly without
ion-ion interactions.
The designed peptides have a charge per unit length of —0.25 which is lower
compared to homopolypeptides like PLL and PLGA which have a charge per unit length
of 1. Designed polypeptides with a charge per unit length of 0.5 have been successfully
assembled into multilayer films with interesting growth properties [253]. The design of
the peptides for the cell culture films was based on the charge properties of the RGD
peptide. The RGD motif has two charged residues arginine (positive) and aspartic acid
(negative) making the motif uncharged at physiological pH. It is also known that RGD
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mediated cell adhesion also depends on the flanking residues. In the designed peptides
these flanking residues have been substituted by glycine, the simplest amino acid. This
design limits the charge on the peptide to =0.25 for a 32 mer. The other peptides have
been designed to have the same charge density at physiological pH. The deposition of the
peptides overall is lower compared to that of highly charged peptides. The presence of
glycine residues (50%) in case of P4 and N4 could also have limited the adsorption of the
peptide. This is relevant because the peptide backbone is very flexible in the vicinity of
glycine residues. During the assembly process the adsorption of P4 and N4 is less favored
than that of others from the point of view of chain entropy.
The CD data shown in Figure 4.4 reflect the differences in the peptide deposition.
CD spectra are sensitive to the secondary structure of the films, which will depend on
different amino acid sequences of designed peptides. The cotton effect amplitudes vary as
P2N2>P3N1>P4N4. The CD spectra show a predominant /3-sheet structure in the case of
P2N2 and a mix of a-helix and /3-sheet in case of P3N1. The CD signal from P4N4 was
very weak and could be due to the sporadic deposition of the peptide as evident from
other characterization techniques.
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Figure 4.4. CD spectra of designed peptide multilayer films.
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The CDProsoftware suite, which includes popular methods for estimating the
secondary structure content of a sample from CD spectra was used to deconvolute far-UV
CD spectra into contributions from a-helix, /3-sheet, /3-tum, and coil. A set of spectra of
model polypeptides or reference proteins of known three dimensional structures is used to
determine the relative contributions of the component spectra and it is assumed that
contributions from individual secondary structures are additive. The reference set
consisted of the far-UV CD spectra of 43 proteins of known secondary structure content.
The programs CONTIN/LL and CDSSTR were used to estimate the secondary structure.
The data are shown below in Table 4.3. The secondary structure of P2N2 was
predominantly /3-sheet and /3-tum which accounted for nearly 80% of the secondary
structure content. P3N1 also approximately had 60% (3-sheet and (3-tum and also showed
some coiled structure. The results of P4N4 cannot be interpreted in a definite way
because of the poor deposition nature of P4N4 and the possibility that light might have
passed through regions o f incomplete coverage during measurement of the spectra.

Table 4.3. Secondary structure content of designed peptide multilayer films.
P3N1
Helix Sheet
Structure
CONTIN/LL 0.034 0.378
CDSSTR
0.016 0.393
P4N4
Helix Sheet
Structure
CONTIN/LL 0.036 0.416
CDSSTR
0.014 0.023
P2N2
Structure
Helix Sheet
CONTIN/LL 0.061 0.596
CDSSTR
0.166 0.401

Turn Coil
0.238 0.350
0.198 0.380
Turn Coil
0.214 0.334
0.023 0.032
Turn
0.227
0.191

Coil
0.115
0.251
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The peptides P2 and N2 were studied using AFM to look at the physical nature of
the aggregates formed. It was suspected that these peptides formed elongated fibril like
structures but upon investigation showed a globular morphology. Peptide P2 or N2 was
adsorbed on a silicon surface for 10 min and then rinsed with DI water and dried before
imaging. It is easy to picture the deposition process of P2 and N2 as a scenario of
hydrophobically driven assembly. Figure 4.5 shows the AFM image of peptide P2
compared with a bare silicon wafer.
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Figure 4.5. AFM image o f peptide P2 on a silicon surface.

The surface morphology of the peptide films varies greatly in accordance with
their amino acid composition and the magnitude of deposition. P2N2 showed a rough
uneven surface with aggregation and a good coverage. P3N1 showed a fibrous
morphology with evenly sized fibers covering the surface. The fiber formation can be
attributed to the hydrogen bonding capability of serine residues in P3 or the disulfide
bonding capability of cysteine residues in N l. P3N1 showed a fibrous morphology with
evenly sized fibers covering the surface. However, after immersing in PBS buffer
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overnight P4N4 showed a better coverage profile when imaged under PBS buffer. The
interstitial spaces could be filled with the buffer or the film might have reorganized in
hydrated conditions as shown in Figure 4.6.
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Figure 4.6. AFM images of designed polypeptide films.

Cells are impacted by various nonspecific environmental factors such as pH, ionic
strength, temperature, surface chemistry, and topography. Surface topography has been
documented to influence a variety of cell behavior and has a role in how a cell responds
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to environmental stimuli. A number of studies have evaluated random nano-scale surface
features defined in terms of surface roughness. Cellular responses reported on these
surfaces vary depending on the material and cell type investigated. It is hard to determine
trends in such cases. It is also difficult to compare the effect of topography based on
comparing surface roughness value Ra which can be the same for two surfaces with very
different features. Surface roughness measurements show that despite having completely
different morphologies P2N2 and P3N1 have the about the same average roughness. The
surface roughness of P4N4 is very low almost 6 times less than P2N2 and P3N1. The root
mean square roughness and average roughness of the films is shown below in Table 4.6.

Table 4.4. Surface roughness of designed peptide multilayer films.
Film

Average Roughness
(nm)
5 /rm
1 jum

Rms Roughness (nm)
5 jum

1 jum

P2N2

3.65

3.17

4.83

3.93

P3N1

3.89

3.32

5.96

4.16

P4N4

0.61

0.57

0.99

0.70

Bare

0.15

0.61

0.21

0.16

Film thickness was higher in the case of P2N2 and varied as P2N2>P3N1>P4N4
as shown in Fig 4-5. The deposition of aggregates in the case of P2N2 might have
contributed to higher thickness for the same number of layers as compared to the others.
The thickness of P3N1 is higher than P4N4 owing to the greater deposition of mass due
to the presence of valine residues. The change in RI with film thickness may need to be
considered when attempting to infer structural information such as layer thickness from
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optical measurements using an assumed RI. The thickness of different peptide films is
shown in Figure 4.7 below.
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Figure 4.7. Ellipsometric thickness of designed polypeptide multilayer films.

The refractive index (RI) of adsorbed protein layers has been reported to vary
from 1.34 to 1.6 [254, 255]; therefore, the thickness was measured at both the extremes
of RI at three independent points on the film surface to obtain an average thickness value
and the average RI was estimated to be around 1.47. The thickess values at various RI are
shown in Table 4.5.

Table 4.5. Film thickness o f peptide multilayer films at various RI values.
Film

Rl=1.34

Rl=1.47

RN1.6

Avg

SD

Avg

SD

Avg

SD

P2N2

17.7

0.4

13.8

0.35

15.75

0.375

P3N1

12

0.76

9.3

0.58

10.65

0.67

P4N4

7.1

0.51

5.5

0.38

6.3

0.445
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The variation of thickness with RI was also measured using a relatively smooth
peptide film P3N3 which had a very good surface coverage as evident from AFM. The
data show that the relationship between film thickness and RI is almost linear as shown in
Figure 4.8 and the average thickness was calculated from the values obtained for the
extremes.
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Figure 4.8. Variation of film thickness with RI. Film P3N3 was taken as a non limiting
example due to its low surface roughness and full coverage.

Mouse 3T3 fibroblast cells were seeded and allowed to grow on peptide
multilayer films and the confluence was monitored. An MTT assay was used to
determine the number of cells growing on the films which was deduced from a standard
curve. Figure 4-10 shows a light microscope image of cells growing on a PLL/PLGA
film.
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Figure 4.9. Mouse 3T3 fibroblasts on PLL/PLGA multilayer film.

Data from the MTT assay show that more number of cells were present on
substrates coated with P4N4 as compared to P2N2 or P3N1. The growth varied as
P4N4>P3N1>P2N2. A bare glass slide and a slide coated with poly-(L-lysine)/poly-(Lglutamic acid) (PLL/PLGA) were used as controls. Maximum proliferation occurred on
the substrates coated with PLL/PLGA as compared with the designed peptides. The
number of cells growing on P2N2 and the control glass slide is almost the same. Cells
were also seeded on films with 10 layers of PLL/PLGA and 5 layers of designed peptide
to study the effect of precursor coatings and also minimize the amount of peptide
required for achieving optimal cell growth. The precursor layers were fabricated from
PLL and PLGA of =1500-3000 Da almost the same molecular weight as the designed
peptides. The data show that the number of cells growing on (PLL/PLGA)-P2N2 and
(PLL/PLGA)-P3N1 was almost the as in the case of P2N2 and P3N1 whereas the number
of cells growing on (PLL-PLGA)-P4N4 decreased by almost 25%. All the films were
fabricated in triplicate to check for reproducibility and the standard deviations in all cases

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

83

are less than 10%. MTT assay data for the different peptide films are shown in figure
4.10 and figure 4.11 below.
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Figure 4.10. Number of cells on polypeptide multilayer films as determined by MTT
assay.
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Figure 4.11. Number of cells growing on (PLL/PLGA)-polypeptide multilayer films as
determined by MTT assay.
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It has been shown that the polypeptide multilayer films can be used as substrates
for cell culture and the properties of the substrate can be controlled by incorporating
specific amino acids in the designed peptides. It is impossible to predict the trend of cell
growth depending on the physical or biochemical properties of the films studied here.
Cells behave differently on different substrates and different cell lines do not show
identical behavior on the same substrate. However, it can be concluded that polypeptide
multilayer films show substantial promise as substrates for cell attachment and growth.
Solid-phase peptide synthesis techniques can be employed to synthesize RGD peptides in
the laboratory. Customizability of RGD peptides enables synthesis of specially designed
RGD containing peptides that can be made to bind specifically to certain integrins for
specific applications.
Certain general design criteria for custom peptides [109], such as using
conformation-restraining residues (Gly and Pro) at specific locations in the sequence,
selectively choosing neighborhood residues of RGD sequence, choosing the locations of
cysteine residues for plausible disulfide bridge formation and cyclization can help design
and engineer RGD-containing peptides for various purposes. “Integrin-selective
peptides” may be designed for specific purposes, in order to enhance integrin affinity,
selectivity, and/or sensitivity of RGD peptides [215]. Synthesis of short RGD peptides
ensures that the RGD motif is available on the surface of the peptide for integrin
interaction, unlike large proteins and peptides where the RGD motifs are not necessarily
available for integrin binding. The presence of inherent RGD motifs in the peptide
sequence also eliminates certain chemical processes required to “RGD-modify” other
polymers. The amino acid sequence and the peptide itself can be subjected to any or all of
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amino acid analysis (AAA), high-performance liquid chromatography (HPLC), mass
spectrometry (MS), or circular dichroism (CD) techniques to ensure the desired
properties and structural features are present in the synthesized peptide.

4.8 Conclusions
Designed polypeptides with inherent RGD motifs can be used in LBL as surface
coatings for cell culture applications. The relationship between film structure, roughness,
thickness, biochemical composition, and the flanking residues can be investigated in
great depth as RGD peptides occur in many different proteins including collagen,
fibronectin, vitronectin and fibrinogen. The experiments show that RGD peptides can be
used for coating surfaces to facilitate cell growth and attachment. RGD peptides can help
in cell recognition, and possible applications of RGD peptide multilayer films can include
enhanced wound healing, skin regeneration, etc. Layer-by-layer assembly of synthetic
RGD peptides is a promising field with potential applications. The data show that low
charge density on a peptide is a key factor in building a multilayer film using LBL. The
fibril formation in the case of peptides P2 and N2 due to hydrophobic interactions is a
result of low charge. However, careful design of peptides with a balance of physical and
biochemical properties can result in well defined films which can mimic the extracellular
matrix and play a key role in understanding cell growth, proliferation, and differentiation
on coated surfaces.
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CHAPTER 5

IN VIVO STUDIES OF DESIGNED POLYPEPTIDE
MICROCAPSULES FOR DRUG DELIVERY
APPLICATIONS

5.1 Introduction
The encapsulation of materials at the macroscopic scale has long been used to
store different solids or liquids and to protect them from environmental influences.
Microencapsulation of materials is of highest interest for various applications in
pharmaceutical, cosmetic, food, textile, adhesive, and agricultural industries. Today,
microcapsule systems have the highest potential in the pharmaceutical industry since
many different requirements have to be fulfilled to deliver a drug at the right moment, in
the right place, and at an adequate concentration. One of the simplest examples is the
protection of orally applied drugs from the attack of acids in the stomach before they can
be adsorbed in the intestine. This problem is solved in many cases by the use of gelatin
microcapsules, which are insoluble at the low pH values found in the stomach allowing
the desired release later in the intestinal tract.
Several approaches have been used to fabricate microcapsules. One approach is to
use systems that self-assemble into capsules at given conditions, such as the aggregation
of lipid molecules into spherically closed bilayer structures like vesicles or liposomes

86
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[256, 257], Block copolymers can also aggregate in aqueous solution to vesicular
structures [258], A second method is to use dendrimers or hyperbranched polymers for
nanoencapsulation [259, 260]. However, the particle preparation requires a rather costly
and tedious procedure, which clearly presents a limiting factor for possible applications.
Another method involves the use of LBL technology [261] which uses a
sacrificial template core that can be dissolved. The LBL assembly process developed for
macroscopic planar surfaces can been adapted to colloidal particles 0.1-10 pm in
diameter for the preparation of capsules [261, 262], Dissolution of the template particles
[263] will yield empty capsules with a wall thickness of 5-50 nm, depending on the
assembly procedure, materials, and cycles of polyion adsorption. In principle, a large
variety of polyelectrolytes could be used as capsule components to yield a
correspondingly broad range of microcapsule functionalities. Haynie et al. [181] used
designed polypeptides containing cysteine residues to form microcapsules and the
polypeptide layers were crosslinked by oxidation, forming disulfide-bond-“locked”
capsules. This process, which is reversible, [117, 121] stabilized the capsules in “harsh”
environments. High-capacity, high-activity loading of glucose oxidase into polypeptide
microcapsules has been achieved by addition of polyethylene glycol 300 (PEG300) to
aqueous solutions of oppositely charged polypeptides used in capsule assembly These
microcapsules have been shown semipermeable to small molecules and allowed the
enzymatic breakdown of the encapsulated glucose oxidase [264], The inherent
biocompatibility of the encapsulating polypeptides presents advantages for biomedical
applications over the more common non-biodegradable synthetic polyelectrolytes.

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

88

5.2 Materials and Methods
Poly ( L-glutamic acid) ( PLGA) (15 kDa), Poly (L-lysine) (PLL) (15 kDa) were
from Sigma-Aldrich (USA). Designed peptide was from Global Peptide Analysis (USA).
Phosphate buffered saline (PBS) was from Invitrogen (USA) and calcium carbonate
microparticles (3pm dia) were from GmbH (Germany) . 18.2 MQ-cm water was used in
all experiments. In additional, all formulations were filtered through 5 pm filter to ensure
low aggregation. Solutions for film capsule assembly were prepared by dissolving the
peptides in PBS to a final concentration of 1 mg/ml.
5.2.1 Microcapsule Fabrication
Two different microcapsule formulations were prepared using LBL technique on
calcium carbonate microparticle templates. In one formulation (formulation 1) the
microcapsules were fabricated using PLL/PLGA with the outermost layer being PLGA.
In another formulation (formulation 2) the microcapsule was fabricated with layers of
PLL/PLGA with the outermost layer being a designed peptide (GDAAECAD)3 GDAAECAY. A formulation with uncoated calcium carbonate microparticles was used a
control. All formulations were prepared to two strengths; a high dose and a low dose. A
typical high dose had 5x 106 microcapsules and a low dose had lxlO 6 microcapsules per
100 pL of formulation.
5.2.2 Animals and Husbandry
BALB/cJ mice used in this study were purchased from Jackson Labs (USA) and
came from a specific-pathogen-free (SPF) colony. 16 males and 16 females at 7 weeks of
age were maintained in isolation rooms in 70 sq in. filter top cages with aspen wood chip
bedding. Care-taking personnel entered the rooms in a specific order to avoid
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contamination and had to wear different protective clothing in each room. The light cycle
in the rooms was 12 hours daily, the room temperature was at 72 F and the rooms had
humidity in the range of 40-70%. All mice were fed 8664 food pellets (6% fat) from
Teklad (USA) and tap water. This study met the standards of the Guide for the Care and
Use o f Laboratory Animals and the study protocol was approved by Institutional Animal
Care and Use (IUCAC) Committee.
5.2.3 Animal Grouping and Coding
The mice were divided into four groups containing eight mice each and all of
them comprised of four females and four males. The males and females in each group
were divided into two subgroups of two males and two females each. The four groups
were labeled as control (C), formulationl (FI), formulation2 (F2), and spare. A mouse
from the spare group was substituted in case of accidental death under trial. Each group
received its own formulation and the male and female subgroups received a high or low
dose. Animals were caged according to the above schematic and were tattooed with
numbers 1 and 2 in each cage. To avoid further confusion one line or two lines were
drawn horizontally across the tails with tattoo ink to identify them. The cages were coded
according to a standard format as Formulation # - Sex - Dose - #. For example if a male
mouse #2 received a high dose of formulation 2 it was labeled as F2-M-H-2. Control
formulation was coded as ‘C ’. In case of a substitution additional number in parenthesis
was included to identify it. For example, if female mouse #1 in the control group which
received a low dose was substituted it was labeled as C-F-L-l(2). The grouping
schematic is shown below in Figure 5.1.
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32 M ice (16 male, 16 female)

High Dose
2 males
2 females

Formulation2 (F2)
4 males
4 females

Formulation 1 (F I)
4 males
4 females

Control
4 males
4 females

Low Dose
2 males
2 females

High Dose
2 males
2 females

High Dose
2 males
2 females

Low Dose
2 males
2 females

Spare
4 males
4 females

Low Dose
2 males
2 females

High Dose
2 males
2 females

Low Dose
2 males
2 females

Figure 5.1. Schematic showing the grouping of mice.

5.2.4 Saphenous Vein Blood Collection
The conscious mouse was restrained in an uncapped 50 ml falcon tube that had
had air holes drilled into the closed end with the mouse’s nose at the closed end of the
tube with the back legs, rear and tail of the animal exposed at the open end of the tube.
The left hind leg was extended and fixed by firmly holding the fold of skin between the
tail and thigh. The skin is held with the same hand holding the restraining tube and the
hair was then removed from the outer surface of the fixed leg using an electric shaver. By
pinching the skin between the tail and thigh of the mouse blood flow was restricted from
the lower limb causing the saphenous vein to protrude. The skin was wiped clean with
70% ethanol and dried with a dry piece of gauze. A small amount of vaseline was wiped
onto the shaved skin to reduce clotting. The saphenous vein was punctured using a 25
gauge needle which was held almost parallel to the vein. Drops of blood were collected
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as they appeared on the surface of the leg in an appropriate capillary tube held on a 45°
angle with one end of the tube at the edge of the drop of blood collecting on the leg
surface. Approximately 300 /d of blood was collected from each mouse using this
method. A second puncture of the same vessel or use of the saphenous vein in the other
leg was done if necessary to collect the desired volume of blood. When the desired
volume of blood has been collected, the blood was dispensed into a 0.5 ml microtube.
The tube was capped and the contents of the tube were mixed by flicking the side of the
tube. The tube of blood was stored under the appropriate conditions (stored on crushed
ice for biochemistry analysis or at room temperature for hematology). To reduce the flow
of blood to the puncture site, the mouse’s foot was flexed and slight pressure was then
applied to the puncture site with a gauze compress until the bleeding stopped The mouse
was then returned to its cage. Figure 5.2 shows a saphenous vein blood draw.

Figure 5.2. Saphenous vein blood collection.
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5.2.5 Tail Vein Injections and Monitoring
For administration of the formulation the mouse was sedated using anesthesia
(isofluorene/oxygen) to restrain it. The tail was rotated slightly to visualize the vein and
was immersed in warm water to dilate it. The tail was then disinfected and a needle
containing the formulation was inserted into the vein at a slight angle. Aspiration is not
possible; instead 100 pL of formulation was injected slowly and observed for clearing of
the lumen. If incorrect positioning resulted in a slight bulge in the tail the needle was
removed and process was repeated proximal to previous site. Upon completion the needle
was removed and the injection site was bandaged for a few minutes before returning the
mouse to its cage. The animals were injected one month apart and then monitored for
signs of illnesses. The animals were weighed daily and a score sheet was developed for
an unbiased decision to euthanize any mouse with signs of disease. The animals were
monitored from a distance to observe eating/drinking, socialization, respiration, and
rough hair coat, hunched posture, tremors and movement and were also handled to
observe crusty eyes, diarrhea on the fur, cool to the touch, blue extremities and other
symptoms. The score sheets were filled out everyday and anything abnormal was noted
down. Figure 5.3 shows a tail vein injection in progress

Figure 5.3. Tail vein injection of formulations.
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5.2.6 Blood Chemistry Analysis
Blood chemistry analysis was performed on a Abaxis Vetscan (USA) machine
with appropriate rotors to load the samples. The analysis was performed under an hour of
collecting the samples to ensure correct readings. The blood was tested for albumin
(ALB), alkaline phosphatase (ALP), alanine amino transferase (ALT), total bilirubin
(TBIL), blood urea nitrogen (BUN), calcium (Ca++), phosphorous (Phos), creatinine
(CRE), glucose (GLU), sodium (Na+), potassium (K+), total protein (TP), and globulins
(GLOB). The analysis was performed on a pre-bleed to act as control and subsequently
blood samples were drawn and analyzed a month after injections.
5.2.7 Euthanasia and Preservation
The animals were euthanized in a humane way using isofluorene as a sedative and
drawing blood from the heart. The mice succumbed due to the loss of blood and were
preserved for the study for gross pathology and tissue analysis. Immediately following
their termination according to the approved protocol, an incision was on the ventral side
of the animals from the throat to the genitalia. The ribs were cracked open to expose the
lungs and other internal organs. The lungs, which deflate over time, were inflated as
follows: a thread was looped over the trachea, and formalin was introduced gently. The
trachea was sutured below the needle point to prevent leakage. Larger organs, such as
the lungs and liver, were cross-sectioned to ensure adequate surface area for the
preservative to seep into the tissues and preserve them. The preservative was 10 %
buffered formalin with a final pH of 6.8. The buffer was phosphate buffered saline.
Figure 5.4 shows the preservation process.
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Figure 5.4 Mice being prepared for preservation.

5.3

Results and Discussion

Generally, all formulations were well tolerated by the mice. Some animals
exhibited a slight ruffle coated appearance at times, but they appeared clinically normal.
Mice treated with the designed polypeptide formulation tolerated the formulation very
well at both levels of dosage. Changes in blood chemistry were monitored after a month
to ensure that the formulations would not give rise to delayed complications. Blood
contains large amounts of proteins, ions, and other metabolites maintained at appropriate
levels to ensure a healthy system. The levels of these metabolites may be elevated or
reduced under certain conditions like infection, inflammation, and stress. The values of
these metabolites in the blood were checked after the formulation injections and were
compared to a prebleed control. Some aspects of the analysis are discussed here.
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The total amount of blood protein and the amounts of the two main protein
groups, albumin and globulin indicate the general state of nutrition and can provide clues
to help diagnose some diseases. Albumin is produced mainly in the liver. It helps
transport some drugs and other substances through the blood and can be broken down to
assist with tissue growth and healing. It also helps prevent blood from leaking out of
blood vessels, so when albumin levels drop, edema may develop, with fluid collecting in
the ankles, lungs, or abdomen. The levels of albumin in the blood before and after
injections are shown below in Figure 5.5. The data show that there is a slight increase in
albumin levels before and after the formulation injections, and it is within the normal
value. Data is averaged for all mice within the same group and the average albumin level
in BalbC mice is usually around 2.5-4.8 g/dL.

Pre-bleed
After first injection
After se c o n d injection

Control

Formulation 1

Formulation 2

Mice Group

Figure 5.5. Albumin levels in mice before and after formulation injections.
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Bilirubin is formed primarily from the breakdown of a substance in red blood cells called
"heme." It is taken up from blood processed through the liver, and then secreted into the
bile by the liver. An increase in the level of bilirubin may be caused by the decreased
removal of bilirubin from the blood stream due to liver disease, or the increased
destruction of red blood cells. Very high levels are usually noticeable as jaundice. The
bilirubin may be elevated in many forms of liver or biliary tract disease, and thus it is also
relatively nonspecific. However, serum bilirubin is generally considered a true test of
liver function, and significant changes in the bilirubin levels would mean that the
formulations could be interfering with the liver's ability to take up, process, and secrete
bilirubin into the bile. The normal level of bilirubin in BalbC mice is usually around 0.10.9 mg/dL. The levels of bilirubin in both the control mice and mice injected with
formulations are within the normal range as shown in Figure 5.6.

0.6
P re-b lee d
A fter first injection
A fter s e c o n d injection

C ontrol

Form ulation 1

Form ulation 2

M ice G ro u p

Figure 5.6. Total bilirubin levels in test mice before and after formulation injection.
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Sodium and potassium are the major positive ions of body fluids. The
concentration of sodium in body fluids is about thirty times the level inside body cells.
The sodium ion content of the blood is a result of a balance between dietary intake and
renal excretion. Only a small percentage is lost through the stool or sweat. Water and
sodium are interrelated - retention of increased sodium is followed by retention of fluid
and vice versa. However, the body can regulate sodium and water separately if necessary.
Potassium is the major positive ion within cells and it is particularly important for
maintaining the electric charge on cell membranes, necessary for neuromuscular
communication, for transporting nutrients into cells and for removing waste products
from cells. Small changes in the potassium levels outside cells can have substantial
effects on the activity of nerves and muscles, particularly with the heart muscle. Low
levels cause increased cardiac activity, which can lead to heart arrhythmia, whereas high
levels decrease heart activity. In extreme circumstances either situation may lead to
cardiac arrest. Figure 5.7a and 5.7b show the levels of sodium and potassium in the
normal ranges of 151-165 mmol/L and 4.6-8 mmol/L respectively.

Pre-bleed
After first injection
After second injection

Pre-bleed
After first injection
After second injection

Control

Formulation 1
Mice Group

Formulation 2

Control

Formulation 1

Formulation 2

Mice Group

Figure 5.7. Levels of blood sodium in the test mice (a) levels of blood potassium in test
mice (b) before and after formulation injections.
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Alanine amino transferase (ALT) is an enzyme located in liver cells and can make
its way into the bloodstream by leaking out of liver cells that are injured. ALT is a
specific indicator of liver inflammation. The reasonable levels of ALT in the data suggest
that the formulations do not cause liver injury. The relatively stable levels of creatinine
show normal kidney function. Creatinine level checks are widely used as a test of renal
(kidney) function both as a general screen, along with urine protein, for kidney disease,
as a test for serial monitoring of kidney function and where there is potential or actual
kidney disease. All mice exhibited normal behavior, continued to consume feed and
water, and did not exhibit abnormal behavior directed at the injection sites (i.e., chewing
or biting). The formulations showed excellent biocompatibility and no foreign body
reaction was observed. The coatings of the capsules are biodegradable which could have
been digested by the enzymes in the blood and assimilated or the capsules could
aggregate in capillary beds like the lungs or the liver. Further histochemical analysis
would be required to address the matter of the “fate” of these microcapsules after
injection.

5.4 Conclusions
Polypeptide microcapsules coated with designed polypeptides can be used as
vehicles for drug delivery and the designed peptide can be engineered to be stable in the
environment into which it is introduced. The biocompatibility and immunogenicity of
polypeptide microcapsules will be more favorable for biomedical applications o f LBL
structures than those made from more usual organic polyelectrolytes, particularly if the
sequences are based on genomic information.
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CHAPTER 6

CONCLUSIONS

Since the development of the LBL technique lots of materials have been used to
assemble multilayer thin films towards understanding the theoretical principles
underlying the technique as well as towards the development of successful patented
applications. In electrostatic LBL assembly of polypeptide multilayer films, assembly is
driven primarily by columbic interactions, but hydrophobic interactions and hydrogen
bonds also contribute to film formation and stability, the amount depending on
polypeptide design.
The field of polypeptide multilayer nanofilm research flourishes where study of
protein structure and function shares a border with development of polyelectrolyte
multilayers. The soil is fertile for creative input and promises a harvest of interesting
results: the structure of a film can be predetermined on a layer-by-layer (LBL) basis, a
huge variety of polypeptide sequences can be realized in large quantities by modem
methods of synthesis, and the fabrication process is environmentally benign. However,
the biomedical applications of polypeptide multilayer nanofilms are still in the early
stages and many await discovery. Promising applications of the polypeptide multilayer
film platform technology include coatings for medical implant devices, scaffolds for
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tissue engineering, coatings for targeted drug delivery, artificial cells for oxygen
therapeutics, and artificial viruses for immunization. In each case peptide structure is
tailored to the application.
The development of polypeptide microcapsules requires effort in the area of
synthesizing biodegradable and biocompatible cores. The tunable semi permeability, high
stability, size range, monodispersity, high interior volumes, multifimctionalization,
modification of physiochemical properties, and the ease and low cost of preparation
opens the way for creating shells with highly specific properties. These properties are of
great potential for drug delivery applications and diagnostics. The investigation of
designed polypeptide multilayer films and microcapsules for biomimetic applications is
almost in its initial stages and many new developments can be expected in future of this
highly fascinating research field.
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Table A.I. UV absorbance data of designed peptide films.
Film

Abs max
(195 nm)

P1N1
P1N2
P1N3
P1N4
P2N1
P2N2
P2N3
P2N4
P3N1
P3N2
P3N3
P3N4
P4N1
P4N2
P4N3
P4N4

0.2
0.2
0.14
0.18
0.09
0.32
0.08
0.11
0.28
0.14
0.14
0.09
0.15
0.09
0.07
0.13

Table A.2. Thickness of designed peptide multilayer films.
Refractive Index =1.34

Refractive Index = 1.6

Refractive Index = 1.47

Film

P1N1
P1N2
P1N3
P1N4
P2N1
P2N2
P2N3
P2N4
P3N1
P3N2
P3N3
P3N4
P4N1
P4N2
P4N3
P4N4

Avg

SD

Avg

SD

Avg

SD

21.9
20
13.9
13
15.8
17.7
13.2
16.6
12
13
12.3
11
15.5
10
14.1
7.1

1.6
1
0.6
0.86
0.525
0.4
1.3
1.7
0.76
0.85
1
1
1.2
0.62
0.62
0.51

17
15.6
10.6
10
12.2
13.8
10.2
12.8
9.3
10
9.5
8.6
12
7.7
11
5.5

1.3
0.8
0.4
0.7
0.425
0.35
1
1.36
0.58
0.64
0.78
0.8
0.9
0.47
0.47
0.38

19.45
17.8
12.25
11.5
14
15.75
11.7
14.7
10.65
11.5
10.9
9.8
13.75
8.85
12.55
6.3

1.45
0.9
0.5
0.78
0.475
0.375
1.15
1.53
0.67
0.745
0.89
0.9
1.05
0.545
0.545
0.445
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Table A.3. Surface roughness values of designed peptide multilayer films.
Sample

P1N1
P1N2
P1N3
P1N4
P2N1
P2N2
P2N3
P2N4
P3N1
P3N2
P3N3
P3N4
P4N1
P4N2
P4N3
P4N4
P2
N2
Bare

Average Roughness (nm)
5 p,m
1 jam
7
4.15
2.07
1.38
3.76
3.65
2.24
1.50
3.89
2.06
0.72
3.31
1.44
2.03
1.53
0.61
2.04
0.88
0.15

6.28
3.34
1.72
0.89
3.45
3.17
1.73
0.98
3.32
1.28
0.52
2.02
0.61
1.72
0.86
0.57
1.32
0.57
0.61

Rms Roug mess (nm)
5 /mi
1 /xm
9
6.29
2.91
1.76
5.42
4.83
3.13
3.35
5.96
3.11
1.08
4.90
2.33
3.24
2.06
0.99
2.80
1.24
0.21

7.82
4.16
2.21
1.15
4.36
3.93
2.18
1.30
4.16
1.64
0.75
2.49
0.79
2.34
1.15
0.70
1.71
0.74
0.16
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Figure A.I. AFM images of designed peptide multilayer films (i).
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Figure A.2. AFM images of designed peptide multilayer films (ii).
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Figure A.3. AFM images of designed polypeptide multilayer films (iii).
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BLOOD CHEMISTRY DATA FOR MICE INJECTED WITH PEPTIDE
FORMULATIONS
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Table B .l. Blood chemistry data for control mice before injections.

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

C-M-H-l

C-M-H-2

3.3
141
22
566
0.3
28
9.7
9.3
0.2
160
162
6.2
6
2.7

3.3
184
28
488
0.3
22
9.4
8.7
0.2
147
157
7.8
5.8
2.4

C-F-H-l

C-F-H-l (2)
3.8
179
32
645
0.3
31
9.6
5.5
0.2
122
161
6.1
6
2.3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

C-M-L-l (2)

C-M-L-2

2.7
145
26
727
0.3
36
9.7
8.8
0.2
141
163
8.5
5.5
2.8

3.5
157
32
527
0.3
31
10.4
9.8
0.2
131
164

C-F-H-2

C-F-L-l

C-F-L-2

4
180
48
595
0.3
18
10
10
0.2
119
159

3.6
159
35
576
0.3
30
9.4
6.3
0.2
144
153
6.9
5.5
1.9

3.1
123
45
521
0.3
22
8.9
3.9
0.2
285
147
4.5
4.8
1.7

C-M-L-l
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6
2

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

-

6.2
2.7

109
Table B.2. Blood chemistry data for control mice after formulation injections.
1- bleed

C-M-H-l

C-M-H-2

C-M-L-l

C-M-L-l (2)

C-M-L-2

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

3.6
136
42
606
0.3
28
10.8
14.4
0.2
122
169
8.5
6.4
2.9

3.2
138
30
531
0.4
28
9.6
5.9
0.2
138
152
6.8
5.7
2.5

3.4
150
80
525
0.4
24
9.7
9.2
0.2
209
160
8.1
5.3
2

3
134
37
583
0.4
24
9.6
8
0.2
140
160
7.4
5.9
2.9

3.3
168
34
530
0.4
24
9.8
5.2
0.2
166
156
6.2
5.9
2.6

C-F-H-l

C-F-H-l (2)

C-F-H-2

C-F-L-l

C-F-L-2

4.1
194
34
625
0.4
18
10.2
6.5
0.2
155
158
6.3
6
1.9

3.8
146
39
643
0.4
24
10.2
9.6
0.2
146
163
7.7
5.7
1.9

3.7
170
73
610
0.4
35
10.5
8.1
0.3
197
155
6.2
5.4
1.7

3.8
155
42
595
0.4
21
10.3
5.1
0.3
160
152
5.2
6
2.1

4
161
57
608
0.4
24
9.9
5.6
0.2
139
151
4.9
5.9
1.9

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB
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Table B.3. Blood chemistry data for FI group mice before injections.
0-bleed

Fl-M-H-1

Fl-M-H-2

Fl-M-L-1

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

3.1
164
20
788
0.3
25
9.9
10.4
0.2
128
154
8
5.6
2.6

2.9
217
64
629
0.6
25
9.2
8.7
0.2
194
146
7.3
5.4
2.4

2.3
94
42
1281
0.4
26
9.6
7.5
0.2
199
143
6.6
4.7
2.4

Fl-F-H-1

Fl-F-H-2

Fl-F-L-1

Fl-F-L-2

3.5
208
34
792
0.3
18
9.5
5.7
0.2
157
153
5.8
5.5
2.1

3.9
178
57
654
0.3
19
10.3
10.9
0.2
139
161
8.2
6.2
2.3

3.6
178
28
608
0.6
16
9.9
6.4
0.2
137
156
6.4
5.5
2

3.7
204
33
618
0.5
15
9.7
4.8
0.2
139
147
5.8
5.9
2.2

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

Fl-M-L-2
-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fl-M-L-2(2)
3.4
137
16
715
0.6
25
9.9
6.5
0.2
148
152
6.1
6.1
2.7
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Table B.4. Blood chemistry data for FI group mice after formulation injections.

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

Fl-M-H-1

Fl-M-H-2

Fl-M-L-1

Fl-M-L-2

Fl-M-L-2(2)

3.4
132
28
571
0.3
34
10.1
6.8
0.2
131
164
7.3
5.9
2.5

3.2
162
35
549
0.4
30
9.3
4.6
0.3
191
152
6
5.7
2.4

3.3
142
28
581
0.4
26
9.8
4.9
0.2
174
151
7.2
5.8
2.5

2.9
130
32
509
0.4
24
9.5
7
0.2
126
154
6.9
5.4
2.5

3.5
126
31
633
0.4
31
10.3
8.4
0.2
167
160
7.9
6.1
2.6

Fl-F-H-1

Fl-F-H-2

Fl-F-L-1

Fl-F-L-2

3.8
160
37
775
0.4
21
9.6
5.2
0.2
128
152
5.9
5.5
1.7

3.7
154
93
721
0.4
29
10.5
12
0.2
142
161
7.2
5.5
1.8

4
170
54
561
0.3
19
10.4
7.4
0.2
176
154
7.1
6.1
2.1

4
165
45
574
0.3
24
10.4
6.7
0.2
155
154
7.7
6.1
2.1
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Table B.5. Blood chemistry data for F2 group mice before injections.

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

F2-M-H-1

F2-M-H-2

F2-M-L-1

F2-M-L-2

2.6
115
306
432
0.3
25
9.2
7.8
0.2
198
155
7.6
4.9
2.3

2.6
133
23
484
0.3
28
9.4
4.8
0.2
251
151
5.8
5
2.4

2.7
144
22
546
0.3
21
9
6.7
0.2
190
152
5.8
4.8
2.1

2.7
146
24
516
0.3
21
9
8.2
0.2
183
151
6
4.7
2.1

F2-F-H-1

F2-F-H-2

F2-F-L-1

F2-F-L-2

3.2
65
85
3516

3.3
95
86

3.7
197
36
636
0.3
18
9.8
6.2
0.2
152
156
5.9
5.7
1.9

3.2
171
44
656
0.3
16
9.3
6.1
0.2
174
151
4.7
5.1
1.8

-

22
10
7
0.2
243
151
-

5.2
2

-

0.3
17
10.3
6.1
0.2
186
154
7.2
5.5
2.2
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Table B.6. Blood chemistry data for F2 group mice after formulation injections.
1- bleed

F2-M-H-1

F2-M-H-2

F2-M-L-1

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

3.2
149
30
511
0.4
29
9.6
6.1
0.2
147
156
5.7
5.4
2.3

3.3
129
30
489
0.4
29
9.6
5.8
0.2
164
154
7.1
5.7
2.4

2.9
110
54
520
0.4
24
9.5
7.2
0.2
189
154
5.8
5.1
2.2

F2-F-H-1

F2-F-H-2

F2-F-L-1

3.7
158
32
642
0.4
20
10.3
7.2
0.2
169
152
6.1
5.6
1.8

3.9
174
37
532
0.3
17
10.5
7
0.2
171
152
7.8
6
2.1

3.9
167
30
506
0.3
19
10
5.7
0.2
159
151
5.3
5.6
1.7

ALB
ALP
ALT
AMY
TBIL
BUN
CA
PHOS
CRE
GLU
NA
K
TP
GLOB

F2-M-L-2
-

-

-

-

-

-

-

-

-

-

-

-

-

-

F2-F-L-2
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-

-

-

-

-

-

-

-

-

-

-

-

-

-
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